Zhongshan Hospital, Fudan University
复旦大学附属中山医院
Listed for 27 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Zhongshan Hospital, Fudan University
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌3 papers led
- Oesophageal squamous cell carcinoma食管鳞状细胞癌56 papers led8 open trials led
- Hepatocellular carcinoma肝细胞癌408 papers led16 open trials led
- Stomach cancer胃癌134 papers led8 open trials led
- Hepatoblastoma肝母细胞瘤3 papers led
- Chordoma脊索瘤0 papers led
- Osteosarcoma骨肉瘤5 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤28 papers led
- Neuroblastoma神经母细胞瘤0 papers led
- Ewing sarcoma尤文肉瘤2 papers led
- Multiple myeloma多发性骨髓瘤23 papers led4 open trials led
- Beta thalassaemiaβ 地中海贫血1 paper led
- Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病0 papers led
- IgG4-related diseaseIgG4相关性疾病4 papers led
- Myasthenia gravis重症肌无力1 paper led1 open trial led
- Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎0 papers led
- Takayasu arteritis大动脉炎33 papers led2 open trials led
- Idiopathic pulmonary fibrosis特发性肺纤维化3 papers led
- Lymphangioleiomyomatosis肺淋巴管平滑肌瘤病1 paper led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症3 papers led
- Duchenne muscular dystrophy杜氏肌营养不良1 paper led
- Behçet disease白塞病2 papers led
- IgA nephropathyIgA 肾病4 papers led
- Osteogenesis imperfecta成骨不全症1 paper led
- Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
- Inherited epidermolysis bullosa遗传性大疱性表皮松解症1 paper led
- Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led
Not listed for: Retinoblastoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Moyamoya disease, Wilson disease, Biliary atresia, Hepatic echinococcosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led 3 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
10 hospitals in Shanghai for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingAdjuvant vs Surgery Only in Early-stage Recurrent NPC
- Phase
- Phase 3
- Started
- 2024-06
- Registry
- NCT06228079
Age 18 years to 75 years (registered criteria)
Led by Eye & ENT Hospital of Fudan University; 6 listed hospitals as study sitesFuzhou, Nanning, Shanghai, Shenzhen
- RecruitingNeoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
- Phase
- Phase 3
- Started
- 2024-07
- Registry
- NCT06235203
Age 18 years to 75 years (registered criteria)
Led by Eye & ENT Hospital of Fudan University; 6 listed hospitals as study sitesFuzhou, Nanning, Shanghai, Shenzhen
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led3
- Deubiquitinating enzyme UCHL1 stabilizes CAV1 to inhibit ferroptosis and enhance docetaxel resistance in nasopharyngeal carcinoma.
- A head-to-head comparison of 18F-FDG PET/CT and 18F-FDG PET/MR in patients with nasopharyngeal carcinoma under different disease settings.
- Effect of Nutritional Intervention on the Management of Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma.
All its trials on ClinicalTrials.gov, any status7
- Adjuvant vs Surgery Only in Early-stage Recurrent NPC
- Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
- Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC
- Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma
- Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)
- Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
More papers found outside PubMed (not counted)1
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 56 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 1.9%.
18 hospitals in Shanghai for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma
Open trials with this hospital 9
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingPatient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
- Phase
- Not given
- Started
- 2025-03
- Registry
- NCT07054086
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingNeoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)
- Phase
- Phase 1
- Started
- 2025-07
- Registry
- NCT07317609
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingBenmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
- Phase
- Phase 2
- Started
- 2024-10
- Registry
- NCT06637163
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan University; 4 listed hospitals as study sitesHangzhou, Shanghai, Shantou, Shenyang, Tianjin
- RecruitingEfficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2023-12
- Registry
- NCT07266493
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingNeoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC
- Phase
- Phase 2/Phase 3
- Started
- 2022-03
- Registry
- NCT04973306
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingNeoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
- Phase
- Not given
- Started
- 2020-12
- Registry
- NCT05740995
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- Not yet recruitingAn Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual Imaging
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07770672
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- Not yet recruitingTwo-field Versus Three-field Lymph Node Dissection in ESCC After Neoadjuvant Therapy
- Phase
- N/A
- Started
- 2022-07
- Registry
- NCT05420480
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingComparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
- Phase
- Phase 3
- Started
- 2019-09
- Registry
- NCT04135664
Age 18 years to 75 years (registered criteria)
Led by Shanghai Chest Hospital; 5 listed hospitals as study sitesNanchang, Shanghai, Tianjin
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led56
- RCN2 facilitates esophageal squamous cellular carcinoma metastasis and cisplatin resistance through UBR5-mediated PPP2CA ubiquitination and degradation.
- Total-Body PET/CT Metabolic Response in Esophageal Squamous Cell Carcinoma.
- Positive Lymph Node Status Before and After Neoadjuvant Chemoradiotherapy Improves Prediction of Disease-Free Survival in Esophageal Squamous Cell Carcinoma Patients.
- Long-term outcome of neoadjuvant tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.
- Suppressing SENP1 inhibits esophageal squamous carcinoma cell growth via SIRT6 SUMOylation.
- Hypoxia-induced PGK1 expression promotes esophageal squamous cell carcinoma progression via stimulating MYH9-mediated GSK3β/β-catenin signalling.
- ZSH-2208: A novel retinoid with potent anti-tumour effects on ESCC stem cells via RARγ-TNFAIP3 axis.
- Individual risk stratification to predict metastasis for ESD of superficial esophageal squamous cell carcinoma.
- Primary Tumour Burden Score: A Novel Staging Parameter for Oesophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy.
- [18F]FDG PET/CT for predicting neoadjuvant PD-L1 blockade monotherapy treatment response in patients with locally advanced esophageal squamous cell carcinoma: a preliminary study.
- SUMO-Specific Peptidase 5 Promotes Oesophageal Squamous Cell Carcinoma Growth through the NF-κB-SLC1A3 Axis.
- Unravelling the difference of immune microenvironment characteristics between esophageal basaloid squamous cell carcinoma and conventional esophageal squamous cell carcinoma.
- Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring.
- Gram-Negative Microflora Dysbiosis Facilitates Tumor Progression and Immune Evasion by Activating the CCL3/CCL5-CCR1-MAPK-PD-L1 Pathway in Esophageal Squamous Cell Carcinoma.
- Tertiary lymphoid structures and clinicopathological characteristics in pT1b Esophageal squamous cell carcinoma.
- Proteogenomic characterization reveals that lipid droplet formation promotes esophageal squamous cell cancer progression.
- Perioperative outcomes and survival after neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma.
- FGFR3 amplification is predictive of poor prognosis in esophageal squamous cell carcinoma patients.
- ELF4 contributes to esophageal squamous cell carcinoma growth and metastasis by augmenting cancer stemness via FUT9.
- Identification of Optimal Parameters for Assessing Lymph Node Status of Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy.
- ASO Author Reflections: Exploring the Best Parameter for Lymph Node Assessment in Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy.
- Development of a TLR-Based Model That Can Predict Prognosis, Tumor Microenvironment, and Drug Response for Esophageal Squamous Cell Carcinoma.
- PPP1r18 promotes tumor progression in esophageal squamous cell carcinoma by regulating the calcineurin-mediated ERK pathway.
- Suppression of SENP3 enhances macrophage alternative activation by mediating IRF4 de-SUMOylation in ESCC progression.
- Genomic profiling and associated B cell lineages delineate the efficacy of neoadjuvant anti-PD-1-based therapy in oesophageal squamous cell carcinoma.
- Abnormal p16 expression and prognostic significance in esophageal squamous cell carcinoma.
- Machine learning to predict lymph node metastasis in T1 esophageal squamous cell carcinoma: a multicenter study.
- Proteomic characterization of esophageal squamous cell carcinoma response to immunotherapy reveals potential therapeutic strategy and predictive biomarkers.
- Expression of SOX4 Significantly Predicts the Risk of Lymph Node Metastasis for Patients With Early-Stage Esophageal Squamous Cell Carcinoma.
- Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial.
- Study on the predictive value of pretreatment peripheral blood inflammatory markers regarding immunotherapy in patients with inoperable advanced or locally advanced oesophageal squamous cell carcinoma.
- miR-30c-5p inhibits esophageal squamous cell carcinoma progression by repressing the PI3K/AKT signaling pathway.
- Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial.
- Development and Validation of PET/CT-Based Nomogram for Preoperative Prediction of Lymph Node Status in Esophageal Squamous Cell Carcinoma.
- PLK1 regulating chemoradiotherapy sensitivity of esophageal squamous cell carcinoma through pentose phosphate pathway/ferroptosis.
- Prognostic significance of CCND1 amplification/overexpression in smoking patients with esophageal squamous cell carcinoma.
- PRP19 Enhances Esophageal Squamous Cell Carcinoma Progression by Reprogramming SREBF1-Dependent Fatty Acid Metabolism.
- Prognostic significance of CDK6 amplification in esophageal squamous cell carcinoma.
- Single-cell transcriptomic analysis deciphers key transitional signatures associated with oncogenic evolution in human intramucosal oesophageal squamous cell carcinoma.
- A comparative analysis of clinicopathological factors and survival between esophageal basaloid squamous cell carcinoma and conventional esophageal squamous cell carcinoma.
- Muscular injury as an independent risk factor for esophageal stenosis after endoscopic submucosal dissection of esophageal squamous cell cancer.
- ClusterNet: a clustering distributed prior embedded detection network for early-stage esophageal squamous cell carcinoma diagnosis.
- Integrative proteogenomic characterization of early esophageal cancer.
- Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial.
- NEK2 promotes the migration and proliferation of ESCC via stabilization of YAP1 by phosphorylation at Thr-143.
- CircCDR1 sponges miR-1290 to regulate cell proliferation, migration, invasion, and apoptosis in esophageal squamous cell cancer.
- Repeat endoscopic submucosal dissection as salvage treatment for local recurrence of esophageal squamous cell carcinoma after initial endoscopic submucosal dissection.
- Simultaneous endoscopic submucosal dissection for synchronous multiple early esophageal squamous cell carcinoma: a propensity score-matched analysis.
- Weighted Correlation Network Analysis of Cancer Stem Cell-Related Prognostic Biomarkers in Esophageal Squamous Cell Carcinoma.
- Prognostic value of visual residual tumour cells (VRTC) for patients with esophageal squamous cell carcinomas after neoadjuvant therapy followed by surgery.
- Integrative genome-scale analysis of immune infiltration in esophageal carcinoma.
- Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
- Prognostic value and characterization of NTRK1 variation by fluorescence in situ hybridization in esophageal squamous cell carcinoma.
- Short- and long-term outcomes of endoscopic submucosal dissection for superficial esophageal squamous cell cancer in patients with prior gastrectomy.
- Residual tumor characteristics of esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.
- Comparative study on artificial intelligence systems for detecting early esophageal squamous cell carcinoma between narrow-band and white-light imaging.
Chinese-language papers (not in the count)3
All its trials on ClinicalTrials.gov, any status29
- Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
- Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)
- Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
- Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
- Two-field Versus Three-field Lymph Node Dissection in ESCC After Neoadjuvant Therapy
- Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC
- Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
- Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC
- Sequential Preoperative Penpulimab Combined With Chemoradiotherapy(CRT) for Locally Advanced Esophageal Squamous Cell Cancer
- Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC
- NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNoma
- Comparison Between NCRT and NCT Followed by MIE for Treatment of Locally Advanced Resectable ESCC
- Long-term Outcomes of Superficial Esophageal Squamous Cell Carcinoma
- Exploring the Optimal Timing of Minimally Invasive Surgery for Esophageal Squamous Cell Carcinoma
- Machine Learning to Predict Lymph Node Metastasis in T1 Esophageal Squamous Cell Carcinoma
- An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual Imaging
- an AI-Driven Four-Tier Invasion Depth Classification for Early Esophageal Cancer
- Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
- Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
- Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.
- Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma
- Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
- A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors
- A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
- Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
- Robot-assisted Esophagectomy Versus Conventional Thoracoscopic Esophagectomy
- Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study
- Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma
- A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma
More papers found outside PubMed (not counted)25
- Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)–guided neoadjuvant (n) treatment (tx) for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis
- 1457P Tumor immune microenvironment subtypes of esophageal squamous cell carcinoma and their strong ability to predict the efficacy of neoadjuvant immunotherapy
- 392. MACHINE LEARNING TO PREDICT LYMPH NODE METASTASIS IN T1 ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A MULTICENTER STUDY
- 399. LYMPH NODE METASTATIC PATTERNS AND SENTINEL LYMPH NODES FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA AFTER DIFFERENT NEOADJUVANT REGIMENS
- 406. EXPLORING THE OPTIMAL TIMING OF MINIMALLY INVASIVE SURGERY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA AFTER NEOADJUVANT CHEMORADIOTHERAPY
- 413. LYMPH NODE MAJOR PATHOLOGIC RESPONSE IS A POTENTIAL PROGNOSTIC FACTOR AFTER NEOADJUVANT CHEMORADIOTHERAPY IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA
- 430. PROGNOSTIC PATTERNS OF LYMPH NODES WITH COMPLETE TREATMENT RESPONSE IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA AFTER NEOADJUVANT CHEMORADIOTHERAPY AND NEOADJUVANT CHEMOTHERAPY
- 780. NEOADJUVANT IMMUNOTHERAPY COMBINED WITH CHEMORADIOTHERAPY VS NEOADJUVANT CHEMORADIOTHERAPY FOR LOCALLY ADVANCED ESOPHAGEAL CARCINOMA (CSTAGEII-III): A MULTI-CENTER PROSPECTIVE RANDOMIZED CLINICAL TRIAL (ICROSS)
- Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.
- Neoadjuvant Immunotherapy combined with Chemoradiotherapy VS. Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma(cStageII-III): Study Protocol For A Multi-center Prospective Randomized Clinical Trial
- SKYSCRAPER-08: A phase III, randomized, double-blind, placebo-controlled study of first-line (1L) tiragolumab (tira) + atezolizumab (atezo) and chemotherapy (CT) in patients (pts) with esophageal squamous cell carcinoma (ESCC).
- Updated efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion gastrointestinal (GI) cancer.
- 145P Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
- Efficacy and safety of anlotinib hydrochloride combined with nivolumab in the treatment of advanced upper gastrointestinal tumor as second-line or later-line therapy: The results of gastric cancer cohort.
- Heterogeneous baseline immune cell infiltration landscape as a predictor of pathological complete response in locally advanced esophageal squamous cell carcinoma (ESCC) following neoadjuvant chemotherapy and immunotherapy: Results from a si
- SINGLE-CELL TRANSCRIPTOMIC ANALYSIS DECIPHERS KEY TRANSITIONAL SIGNATURES ASSOCIATED WITH ONCOGENIC EVOLUTION IN HUMAN INTRAMUCOSAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA
- SINGLE-CELL TRANSCRIPTOMIC ANALYSIS DECIPHERS KEY TRANSITIONAL SIGNATURES ASSOCIATED WITH ONCOGENIC EVOLUTION IN HUMAN INTRAMUCOSAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA
- 15P Prediction for pCR after neoadjuvant immunotherapy combined with chemotherapy using single-cell RNA sequencing in patients with locally advanced esophageal squamous cell carcinoma (escc): A single-arm phase II clinical trial
- 325. THE ASSOCIATED RISK BETWEEN SINGLE NUCLEOTIDE POLYMORPHISMS OF AP1S1 AND ESOPHAGEAL SQUAMOUS CELL CARCINOMA IN CHINESE POPULATION
- 380. UTILITY OF PET/CT FOR LYMPH NODE METASTASIS DETECTION IN PT1 EARLY ESOPHAGEAL SQUAMOUS CELL CARCINOMA
- Additional file 6 of Silencing of histone deacetylase 3 suppresses the development of esophageal squamous cell carcinoma through regulation of miR-494-mediated TGIF1
- Rare event of NTRK3 rearrangement and amplification in esophageal squamous cell carcinoma
- Rare event of NTRK3 rearrangement and amplification in esophageal squamous cell carcinoma
- circHIPK3 regulates cell proliferation and migration by sponging microRNA-124 and regulating serine/threonine kinase 3 expression in esophageal squamous cell carcinoma
- Robot-assisted Versus Conventional Minimally Invasive Esophagectomy for Resectable Esophageal Squamous Cell Carcinoma
Cancer
Hepatocellular carcinoma
肝细胞癌Led 408 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 2.8%.
15 hospitals in Shanghai for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma
Open trials with this hospital 41
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingEfficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study
- Phase
- N/A
- Started
- 2026-01
- Registry
- NCT06794073
Age 18 years to 80 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingA Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07328009
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingBecotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-04
- Registry
- NCT07536789
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingCamrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
- Phase
- Phase 2/Phase 3
- Started
- 2025-02
- Registry
- NCT06796803
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan University; 1 listed hospital as study siteHarbin, Shanghai
- RecruitingHAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
- Phase
- Phase 2
- Started
- 2025-03
- Registry
- NCT06860490
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingLenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07047586
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingTauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
- Phase
- Phase 2
- Started
- 2025-08
- Registry
- NCT07100392
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingTACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment
- Phase
- Not given
- Started
- 2025-08
- Registry
- NCT07100405
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingDifferent First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment
- Phase
- Not given
- Started
- 2025-09
- Registry
- NCT07147101
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingSymbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
- Phase
- Phase 1/Phase 2
- Started
- 2025-12
- Registry
- NCT07227012
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingBiomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion Therapy
- Phase
- Not given
- Started
- 2024-05
- Registry
- NCT06382103
Age not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingAnti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC
- Phase
- Not given
- Started
- 2024-08
- Registry
- NCT06537908
Age 18 years to 90 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingEfficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy
- Phase
- Phase 2
- Started
- 2022-07
- Registry
- NCT06870942
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- Not yet recruitingThe Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
- Phase
- Not given
- Started
- 2026-07
- Registry
- NCT07724951
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan University; 6 listed hospitals as study sitesGuangzhou, Harbin, Nanning, Qingdao, Shanghai
- Not yet recruitingNIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC
- Phase
- Phase 2
- Started
- 2026-11
- Registry
- NCT07919717
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- Not yet recruitingA Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer
- Phase
- Phase 2
- Started
- 2025-05
- Registry
- NCT06935175
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingFirst in Human Study of SIM0610 in Solid Tumors
- Phase
- Phase 1
- Started
- 2026-01
- Registry
- NCT07348211
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChongqing, Harbin, Shanghai, Shenyang
- RecruitingA Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
- Phase
- Phase 2/Phase 3
- Started
- 2026-03
- Registry
- NCT07490262
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
- Phase
- Phase 2
- Started
- 2026-03
- Registry
- NCT07521852
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesFuzhou, Shanghai
- RecruitingA Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
- Phase
- Phase 1/Phase 2
- Started
- 2026-05
- Registry
- NCT07547553
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin
- RecruitingA Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
- Phase
- Phase 1
- Started
- 2025-04
- Registry
- NCT06858813
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai
- RecruitingJS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-05
- Registry
- NCT06954467
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Harbin, Hefei, Nanchang, Shanghai, Shenyang, Zhengzhou
- RecruitingA Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-06
- Registry
- NCT06986785
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingPhase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2025-11
- Registry
- NCT07176650
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou
- RecruitingABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- Phase
- Phase 2
- Started
- 2025-06
- Registry
- NCT07327034
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou
- RecruitingMDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
- Phase
- Phase 1
- Started
- 2025-08
- Registry
- NCT07391839
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesFuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Shanghai, Zhengzhou
- RecruitingA Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
- Phase
- Phase 2
- Started
- 2024-08
- Registry
- NCT06349980
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingHRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2024-10
- Registry
- NCT06515314
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
- Phase
- Phase 3
- Started
- 2023-01
- Registry
- NCT05489289
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingCT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
- Phase
- Phase 1
- Started
- 2023-10
- Registry
- NCT06560827
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou
- RecruitingOri-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
- Phase
- Phase 1/Phase 2
- Started
- 2022-12
- Registry
- NCT05652920
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Hangzhou, Shanghai
- RecruitingPhase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2021-11
- Registry
- NCT05024214
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Tianjin, Zhengzhou, Zhuhai
- Not yet recruitingA Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma
- Phase
- Phase 2/Phase 3
- Started
- 2026-03
- Registry
- NCT07392866
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai
- Not yet recruitingA Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07682272
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingA Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
- Phase
- Phase 3
- Started
- 2026-11
- Registry
- NCT07691762
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai
- Not yet recruitingJS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer
- Phase
- Phase 3
- Started
- 2026-10
- Registry
- NCT07823348
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Shanghai
- Not yet recruitingPhase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs
- Phase
- Phase 1
- Started
- 2026-11
- Registry
- NCT07861425
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai
- Not yet recruitingSurgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2026-12
- Registry
- NCT07866612
Age 18 years to 80 years (registered criteria)
Led by West China Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai
- Not yet recruiting29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
- Phase
- Not given
- Started
- 2025-08
- Registry
- NCT07100236
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wenzhou, Zhengzhou
- Not yet recruitingA Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07239986
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHefei, Shanghai
- Not yet recruitingA Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
- Phase
- Phase 2/Phase 3
- Started
- 2023-09
- Registry
- NCT05976568
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led408
- DNMT2-m5C-ACLY Axis Promotes Lenvatinib Resistance in Hepatocellular Carcinoma Through Histone Acetylation-Mediated Notch Pathway.
- Application of targeted deep sequencing for management of hepatocellular carcinoma in a real-world setting: prediction of MRD and adjuvant lenvatinib response.
- Hypoxia-related CircARSB Modulates lipid metabolism and innate immune crosstalk to influence immune checkpoint inhibitor response in hepatocellular carcinoma.
- Comparison of repeat hepatectomy with radiofrequency ablation for the survival of hepatocellular carcinoma with solitary intrahepatic recurrence after hepatectomy.
- Combined therapy with microwave ablation and conventional transarterial chemoembolization for hepatocellular carcinoma tumors larger than five centimetres: a prospective study.
- Quantitative sonazoid contrast-enhanced ultrasound features for predicting microvascular invasion of hepatocellular carcinoma.
- LI-RADS nonradiation treatment response assessment version 2024: diagnostic performance in HCC treated with transarterial chemoembolization.
- The MASTL/YBX1/PAK4 axis regulated by stress-activated STK24 triggers lenvatinib resistance and tumor progression in HCC.
- CAD manipulates tumor intrinsic DHO/UBE4B/NF-κB pathway and fuels macrophage cross-talk, promoting HCC metastasis.
- Targeting aerobic glycolysis combats tyrosine kinase inhibitor resistance of hepatocellular carcinoma.
- Dynamic contrast-enhanced ultrasound with quantitative analysis optimizes LI-RADS for hepatocellular carcinoma diagnosis: a multicenter study.
- Graft PD-L1 as a predictive marker for rejection in PD-1 inhibitor therapy for recurrent liver tumors after transplant: A prospective pilot trial.
- Integrating Contrast-Enhanced Ultrasound Features and Serum Biomarkers in an Online Tool Optimizes Noninvasive Hepatocellular Carcinoma Diagnosis.
- miR-32-5p suppresses the progression of hepatocellular carcinoma by regulating the GSK3β/NF-κB signaling.
- Targeting Deltex E3 Ubiquitin Ligase 2 Inhibits Tumor-associated Neutrophils and Sensitizes Hepatocellular Carcinoma Cells to Immunotherapy.
- PIP5K1A Suppresses Ferroptosis and Induces Sorafenib Resistance by Stabilizing NRF2 in Hepatocellular Carcinoma.
- Lactylation-Driven NUPR1 Promotes Immunosuppression of Tumor-Infiltrating Macrophages in Hepatocellular Carcinoma.
- Comprehensive Characterization of Atypical Serum Albumin N-Glycosylation Reveals Hepatocellular Carcinoma Diagnostic Biomarkers.
- ChatExosome: An Artificial Intelligence (AI) Agent Based on Deep Learning of Exosomes Spectroscopy for Hepatocellular Carcinoma (HCC) Diagnosis.
- Diagnostic performances of adding transition and hepatobiliary phase to washout in gadoxetic acid-enhanced MRI for subcentimeter hepatocellular carcinoma.
- Habitat-derived radiomics analysis based on dual lesion for the prediction of microvascular invasion in bifocal hepatocellular carcinoma.
- Enhanced diagnostic performance for subcentimeter hepatocellular carcinoma using a novel criterion integrating serum AFP levels and gadolinium-based contrast-enhanced MRI features.
- Development of a novel diagnostic model integrating microRNAs and GALAD for HBV-related hepatocellular carcinoma.
- Cancer-derived exosomal circTMEM56 enhances the efficacy of HCC radiotherapy through the miR-136-5p/STING axis.
- Assessment of intrahepatic cholangiocarcinoma with LI-RADS in the high-risk population: MRI diagnosis and postoperative survival.
- Phase 2 study of serplulimab with the bevacizumab biosimilar HLX04 in the first-line treatment of advanced hepatocellular carcinoma.
- LCAT deficiency promotes hepatocellular carcinoma progression and lenvatinib resistance by promoting triglyceride catabolism and fatty acid oxidation.
- ACE2 Enhances Sensitivity to PD-L1 Blockade by Inhibiting Macrophage-Induced Immunosuppression and Angiogenesis.
- Targeting MED23 inhibits hepatocellular carcinoma development by suppressing compensatory proliferation and facilitating ROS-mediated cell death.
- SIRPα blockade therapy potentiates immunotherapy by inhibiting PD-L1+ myeloid cells in hepatocellular carcinoma.
- tRF-3a-Pro: A Transfer RNA-Derived Small RNA as a Novel Biomarker for Diagnosis of Hepatitis B Virus-Related Hepatocellular Carcinoma.
- CLDN4 palmitoylation promotes hepatic-to-biliary lineage transition and lenvatinib resistance in hepatocellular carcinoma.
- Harnessing alternative splicing for off-the-shelf mRNA neoantigen vaccines in hepatocellular carcinoma.
- Targeting MORF4L1-mediated DNA repair potentiates RT-induced antitumor immunity via cGAS-STING activation in hepatocellular carcinoma.
- Prognostic value of tumor microenvironment-based molecular subtypes in hepatocellular carcinoma patients undergoing surgery for spinal metastases: refining conventional scoring systems.
- Integrated molecular characterization of sarcomatoid hepatocellular carcinoma.
- Metabolic enzyme PFKFB3 mediates matrix stiffness-potentiated tumour growth and radiotherapeutic resistance in HCC.
- Lysine-specific demethylase 1 deletion reshapes tumour microenvironment to overcome acquired resistance to anti-programmed death 1 therapy in liver cancer.
- Personalized MRD Assessment in Perisurgical ctDNA for Prognostic Prediction in Hepatocellular Carcinoma.
- Landscape analysis of m5C modification regulators unveils DNMT1-mediated dysregulated pyrimidine metabolism in hepatocellular carcinoma.
- Diagnostic value of contrast-enhanced ultrasound in serum biomarker negative hepatocellular carcinoma and colorectal cancer liver metastasis.
- Circulating tumor DNA in peripheral blood may predict the efficacy of immune-targeted therapy in patients with hepatocellular carcinoma.
- Bismuth-based mesoporous nanoball carrying sorafenib for synergistic photothermal and molecularly-targeted therapy in an orthotopic hepatocellular carcinoma xenograft mouse model.
- Construction of a Cancer Stem Cell related Histone Acetylation Regulatory Genes Prognostic Model for Hepatocellular Carcinoma via Bioinformatics Analysis: Implications for Tumor Chemotherapy and Immunity.
- Genetic alterations are related to clinicopathological features and risk of recurrence/metastasis of hepatocellular carcinoma.
- MRI-based predictive model with obesity metabolic phenotype for postoperative survival in HBV-related hepatocellular carcinoma.
- Preoperative identification of hepatocellular carcinoma from focal liver lesions ≤ 20 mm in high-risk patients using clinical and contrast-enhanced ultrasound features.
- 3D-CEUS/MRI-CEUS fusion imaging vs 2D-CEUS after locoregional therapies for hepatocellular carcinoma: a multicenter prospective study of therapeutic response evaluation.
- Matrix Stiffness Promotes Invasion and Metastasis of Hepatocellular Carcinoma via a New Mechanoresponsive SCD1/HMMR Pathway.
- Serum Galectin-9 mirrors immune-evasive microenvironment and predicts early recurrence in hepatocellular carcinoma.
- Safety and efficacy of hypofractionated radiotherapy combined with tyrosine kinase inhibitors in patients with lung metastases after liver transplantation for hepatocellular carcinoma.
- Distinct immune microenvironment of venous tumor thrombus in hepatocellular carcinoma at single-cell resolution.
- LRP4 mutations promote tumor progression and resistance to anti-PD-1 therapy in recurrent hepatocellular carcinoma.
- Cordycepin mediates pyroptosis in HCC through the upregulation of TXNIP and synergizes with anti-PD-L1 immunotherapy.
- Is it necessary to distinguish between combined hepatocellular carcinoma-cholangiocarcinoma with less than 10% of cholangiocarcinoma components versus hepatocellular carcinoma?
- Predictive value of neutrophil-to-lymphocyte ratio in recurrent HCC after repeat hepatectomy or salvage liver transplantation.
- ALOXE3 transcriptionally regulated by activating transcription factor 3 promotes HCC ferroptosis via ERK and JNK signaling pathway.
- Increased CAPG inhibits ferroptosis to drive tumor proliferation and sorafenib resistance in hepatocellular carcinoma via the WDR74-p53-SLC7A11 pathway.
- Plasma metabolomic profiling for hepatocellular carcinoma diagnosis and microvascular invasion prediction.
- External Beam Radiation therapy After Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone for Treatment of Inoperable Hepatocellular Carcinoma: A Randomized Phase 3 Trial.
- Sequential HAIC-TACE combined with targeted and immunotherapy in hepatocellular carcinoma: a quality improvement study.
- Immunometabolite L-2-HG promotes epigenetic modification of exhausted T cells and improves antitumor immunity.
- Targeting immunosuppressive macrophages by CSRP2-regulated CCL28 signaling sensitizes hepatocellular carcinoma to lenvatinib.
- FMO2+ cancer-associated fibroblasts sensitize anti-PD-1 therapy in patients with hepatocellular carcinoma.
- Safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria.
- Low-intensity pulsed ultrasound affects proliferation and migration of human hepatocellular carcinoma cells.
- Fluorescent Probes Targeting Acyl-CoA Synthetase Long-Chain Family Member 4 for Intraoperative Imaging of Hepatocellular Carcinoma.
- Patients with hepatocellular carcinoma with triple-positive tumor markers may benefit from postsurgery adjuvant treatment.
- The genomic and epigenomic abnormalities of plasma cfDNA as liquid biopsy biomarkers to detect hepatocellular carcinoma: a multicenter cohort study.
- The Association Between Tumor Radiomic Analysis and Peritumor Habitat-Derived Radiomic Analysis on Gadoxetate Disodium-Enhanced MRI With Microvascular Invasion in Hepatocellular Carcinoma.
- GlyTrait: A Versatile Bioinformatics Tool for Glycomics Analysis.
- SGMS2+ macrophages enhance NR4A3hi NK cell infiltration to improve prognosis and PD-1 treatment efficacy in hepatocellular carcinoma.
- Survival in patients with unresectable hepatocellular carcinoma: TCC cocktail plus TACE vs TACE alone prospective randomized clinical trial.
- Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial.
- Fucoidan Improves Tumour Control and Liver Function in TACE for Unresectable Hepatocellular Carcinoma: A Randomised Trial.
- P53 status combined with MRI findings for prognosis prediction of single hepatocellular carcinoma.
- Liver-specific paraoxonase-1 alleviates regulatory T cell-driven immunosuppression via metabolic reprogramming in hepatocellular carcinoma.
- Targeting tumor-intrinsic BCL9 reverses immunotherapy resistance by eliciting macrophage-mediated phagocytosis and antigen presentation.
- Metabolism archetype cancer cells induce protumor TREM2+ macrophages via oxLDL-mediated metabolic interplay in hepatocellular carcinoma.
- A glucose-enriched lung pre-metastatic niche triggered by matrix stiffness-tuned exosomal miRNAs in hepatocellular carcinoma.
- 6-aminonicotinamide, a G6PD inhibitor, mitigates CAPS1 reduction mediated HCC metastasis via ERK and GSK3β signals.
- Targeting JMJD6/PPARγ/GPX4 axis overcomes ferroptosis resistance and enhances therapeutic efficacy in hepatocellular carcinoma.
- Juglone induces ferroptotic effect on hepatocellular carcinoma and pan-cancer via the FOSL1-HMOX1 axis.
- MRI-based Intra- and Peritumoral Heterogeneity in Hepatocellular Carcinoma for Microvascular Invasion Prediction and Prognostic Risk Stratification.
- Cathepsin S regulates ferroptosis sensitivity in hepatocellular carcinoma through the KEAP1-NRF2 signaling pathway.
- Targeting HMGB2 acts as dual immunomodulator by bolstering CD8+ T cell function and inhibiting tumor growth in hepatocellular carcinoma.
- Differential expression pattern of CC chemokine receptor 7 guides precision treatment of hepatocellular carcinoma.
- Cross-Referencing Multifluid Metabolic Profiles on Hollow Dodecahedral Nanocages for Enhanced Disease Status Identification.
- CPZ: A Highly Sensitive Diagnostic Biomarker for the Differentiation Between Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma, Particularly in Poorly Differentiated Hepatocellular Carcinoma.
- Impact of steatotic liver disease on hepatitis B-related hepatocellular carcinoma: MRI manifestation and prognostic potential.
- A preoperative nomogram with MR elastography in identifying cytokeratin 19 status of hepatocellular carcinoma.
- Alisertib impairs the stemness of hepatocellular carcinoma by inhibiting purine synthesis.
- Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial.
- Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial.
- An early relapse prediction model based on pathological features following neoadjuvant immunotherapy for hepatocellular carcinoma.
- Contrast-enhanced Ultrasound Features of Primary Hepatic Lymphoma Are Different From Common Malignant Hepatic Tumors: A Comparative Study.
- Ras-related protein Rab24 plays a predictive role in hepatocellular carcinoma and enhanced tumor proliferation.
- Ultrasound findings of hepatic epithelioid hemangioendothelioma: comparison with other malignant hepatic tumors.
- MRI-based radiomics signature: a potential imaging biomarker for prediction of microvascular invasion in combined hepatocellular-cholangiocarcinoma.
- Association of magnetic resonance imaging-derived sarcopenia with outcomes of patients with hepatocellular carcinoma after hepatectomy.
- Value of magnetic resonance imaging for diagnosis of LR‑3 and LR-4 lesions coexisting with hepatocellular carcinoma.
- LI-RADS version 2018 treatment response algorithm on extracellular contrast-enhanced MRI in patients treated with transarterial chemoembolization for hepatocellular carcinoma: diagnostic performance and the added value of ancillary features
- Detecting microvascular invasion in hepatocellular carcinoma using the impeded diffusion fraction technique to sense macromolecular coordinated water.
- How to differentiate between combined hepatocellular carcinoma-cholangiocarcinoma and intrahepatic cholangiocarcinoma with rim arterial phase hyperenhancement?
- Component prediction in combined hepatocellular carcinoma-cholangiocarcinoma: habitat imaging and its biologic underpinnings.
- The value of varying diffusion curvature MRI for assessing the microvascular invasion of hepatocellular carcinoma.
- A multi-parameter intrahepatic cholangiocarcinoma scoring system based on modified contrast-enhanced ultrasound LI-RADS M criteria for differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma.
- Yttrium-90 Transarterial Radioembolization: An Effective Primary or Salvage Therapy to Bridge the Patients with Hepatocellular Carcinoma to Liver Transplantation.
- Increased PRP19 in Hepatocyte Impedes B Cell Function to Promote Hepatocarcinogenesis.
- RECQL4 Inhibits Radiation-Induced Tumor Immune Awakening via Suppressing the cGAS-STING Pathway in Hepatocellular Carcinoma.
- Identification of a DNA damage repair-related LncRNA signature for predicting the prognosis and immunotherapy response of hepatocellular carcinoma.
- Uncovering essential anesthetics-induced exosomal miRNAs related to hepatocellular carcinoma progression: a bioinformatic investigation.
- HuR facilitates miR-93-5p-induced activation of MAP3K2 translation via MAP3K2 3'UTR ARE2 in hepatocellular carcinoma.
- Targeting non-coding RNAs and N6-methyladenosine modification in hepatocellular carcinoma.
- HSP90a promotes the resistance to oxaliplatin in HCC through regulating IDH1-induced cell competition.
- Hypoxia-activated cascade nanovaccine for synergistic chemoembolization-immune therapy of hepatocellular carcinoma.
- Peripheral Lymphocytes in Primary Liver Cancers: Elevated NK and CD8+ T Cells and Dysregulated Selenium Metabolism.
- Stratifying ICIs-responsive tumor microenvironment in HCC: from parsing out immune-hypoxic crosstalk to clinically applicable MRI-radiomics models.
- Clinical characteristics and prognosis of liver injury induced by immune checkpoint inhibitors in patients with malignancies: A real-world retrospective study.
- Effect of Serum Interleukin-6 Concentration on the Prognosis After Radiotherapy for Patients With Hepatocellular Carcinoma.
- Precision treatment in advanced hepatocellular carcinoma.
- Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti-PD-1 therapy in hepatocellular carcinoma.
- Epidemiological and clinical characteristics of hepatocellular carcinoma in Xiamen.
- Diffusion-based virtual MR elastography for predicting recurrence of solitary hepatocellular carcinoma after hepatectomy.
- Chemokine CCL21 determines immunotherapy response in hepatocellular carcinoma by affecting neutrophil polarization.
- A synergistic regulation works in matrix stiffness-driven invadopodia formation in HCC.
- Deciphering the immune modulation through deep transcriptomic profiling and therapeutic implications of DNA damage repair pattern in hepatocellular carcinoma.
- Olaparib enhances radiation-induced systemic anti-tumor effects via activating STING-chemokine signaling in hepatocellular carcinoma.
- Tumor-associated macrophage-induced circMRCKα encodes a peptide to promote glycolysis and progression in hepatocellular carcinoma.
- TGF-β1/SMAD3-driven GLI2 isoform expression contributes to aggressive phenotypes of hepatocellular carcinoma.
- Effective Antiviral Therapy Improves Immunosuppressive Activities in the Immune Microenvironment of Hepatocellular Carcinoma by Alleviating Inflammation and Fibrosis.
- Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy.
- High-throughput intact Glycopeptide quantification strategy with targeted-MS (HTiGQs-target) reveals site-specific IgG N-glycopeptides as biomarkers for hepatic disorder diagnosis and staging.
- BNIP3-mediated mitophagy boosts the competitive growth of Lenvatinib-resistant cells via energy metabolism reprogramming in HCC.
- Synergistic immunochemotherapy targeted SAMD4B-APOA2-PD-L1 axis potentiates antitumor immunity in hepatocellular carcinoma.
- Proteomic and metabolomic features in patients with HCC responding to lenvatinib and anti-PD1 therapy.
- SMYD5 is a ribosomal methyltransferase that catalyzes RPL40 lysine methylation to enhance translation output and promote hepatocellular carcinoma.
- Targeting GSDME-mediated macrophage polarization for enhanced antitumor immunity in hepatocellular carcinoma.
- DDR2/STAT3 Positive Feedback Loop Mediates the Immunosuppressive Microenvironment by Upregulating PD-L1 and Recruiting MDSCs in Oxaliplatin-Resistant HCC.
- GALNT6 drives lenvatinib resistance in hepatocellular carcinoma through autophagy and cancer-associated fibroblast activation.
- Downregulation of GPX8 in hepatocellular carcinoma: impact on tumor stemness and migration.
- Radiotherapy enhances efficacy of PD-1 inhibitors in advanced hepatocellular carcinoma: A propensity-matched real-world study.
- Increased IFN-β indicates better survival in hepatocellular carcinoma treated with radiotherapy.
- Whole-exome sequencing-based mutational profiling of hepatocellular adenoma malignant transformation to hepatocellular carcinoma.
- JCAD deficiency attenuates activation of hepatic stellate cells and cholestatic fibrosis.
- Single-cell multi-modal chromatin profiles revealing epigenetic regulations of cells in hepatocellular carcinoma.
- Contrast-enhanced ultrasound features of hepatic sarcomatoid carcinoma different from hepatocellular carcinoma.
- Development of a Combined Oxidative Stress and Endoplasmic Reticulum Stress-Related Prognostic Signature for Hepatocellular Carcinoma.
- Risk Factors for Postoperative Nausea and Vomiting After TACE: A Prospective Cohort Study.
- Gelation embolism agents suppress clinical TACE-incited pro-metastatic microenvironment against hepatocellular carcinoma progression.
- Preoperative prediction of microvascular invasion in hepatocellular carcinoma using diffusion-weighted imaging-based habitat imaging.
- Diagnostic algorithm for subcentimeter hepatocellular carcinoma using alpha-fetoprotein and imaging features on gadoxetic acid-enhanced MRI.
- A multi-center diagnostic system for intrahepatic mass-forming cholangiocarcinoma based on preoperative MRI and clinical features.
- Sulfiredoxin-1 promotes the growth of hepatocellular carcinoma by inhibiting TFEB-mediated autophagy and lysosome biogenesis.
- Cancer-associated fibroblasts contributed to hepatocellular carcinoma recurrence and metastasis via CD36-mediated fatty-acid metabolic reprogramming.
- Dynamic changes of gut microbiota in mouse models of metabolic dysfunction-associated steatohepatitis and its transition to hepatocellular carcinoma.
- Transferrin receptor 1 promotes hepatocellular carcinoma progression and metastasis by activating the mTOR signaling pathway.
- CBX1 is involved in hepatocellular carcinoma progression and resistance to sorafenib and lenvatinib via IGF-1R/AKT/SNAIL signaling pathway.
- Activation of Wnt/β-catenin signaling promotes immune evasion via the β-catenin/IKZF1/CCL5 axis in hepatocellular carcinoma.
- Platelet-to-lymphocyte ratio predicts tumor response and survival of patients with hepatocellular carcinoma undergoing immunotherapies.
- Inhibition of SIRT1 relieves hepatocarcinogenesis via alleviating autophagy and inflammation.
- Deubiquitination of CIB1 by USP14 promotes lenvatinib resistance via the PAK1-ERK1/2 axis in hepatocellular carcinoma.
- Multi-Omics profiling identifies aldehyde dehydrogenase 2 as a critical mediator in the crosstalk between Treg-mediated immunosuppression microenvironment and hepatocellular carcinoma.
- WWOX tuning of oleic acid signaling orchestrates immunosuppressive macrophage polarization and sensitizes hepatocellular carcinoma to immunotherapy.
- Inhibiting PLA2G7 reverses the immunosuppressive function of intratumoral macrophages and augments immunotherapy response in hepatocellular carcinoma.
- Effects of the subtypes of apolipoprotein E on immune inhibition and prognosis in patients with Hepatocellular Carcinoma.
- Enhancing hepatocellular carcinoma management: prognostic value of integrated CCL17, CCR4, CD73, and HHLA2 expression analysis.
- STRN3 promotes tumour growth in hepatocellular carcinoma by inhibiting the hippo pathway.
- Efficient gene delivery by multifunctional star poly (β-amino ester)s into difficult-to-transfect macrophages for M1 polarization.
- CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma.
- Development and Preliminary Validation of a Novel Convolutional Neural Network Model for Predicting Treatment Response in Patients with Unresectable Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy.
- Evaluate the Microvascular Invasion of Hepatocellular Carcinoma (≤5 cm) and Recurrence Free Survival with Gadoxetate Disodium-Enhanced MRI-Based Habitat Imaging.
- MRI for Hepatitis B-Associated Intrahepatic Cholangiocarcinoma: A Multicenter Comparative Study.
- Successful treatment of tumor lysis syndrome associated with hepatic artery infusion chemotherapy in a patient with hepatocellular carcinoma: a case report.
- Application of a single-cell-RNA-based biological-inspired graph neural network in diagnosis of primary liver tumors.
- Optimizing of a suitable protocol for isolating tissue-derived extracellular vesicles and profiling small RNA patterns in hepatocellular carcinoma.
- A Transformer-Based microvascular invasion classifier enhances prognostic stratification in HCC following radiofrequency ablation.
- Single-cell tumor heterogeneity landscape of hepatocellular carcinoma: unraveling the pro-metastatic subtype and its interaction loop with fibroblasts.
- GOLM1 dictates acquired Lenvatinib resistance by a GOLM1-CSN5 positive feedback loop upon EGFR signaling activation in hepatocellular carcinoma.
- SIGLEC15, negatively correlated with PD-L1 in HCC, could induce CD8+ T cell apoptosis to promote immune evasion.
- Identification of Fasudil as a collaborator to promote the anti-tumor effect of lenvatinib in hepatocellular carcinoma by inhibiting GLI2-mediated hedgehog signaling pathway.
- Stigmasterol: Remodeling gut microbiota and suppressing tumor growth through Treg and CD8+ T cells in hepatocellular carcinoma.
- Activation of NOD1 on tumor-associated macrophages augments CD8+ T cell-mediated antitumor immunity in hepatocellular carcinoma.
- Multiscale Structured Trimetal Oxide Heterojunctions for Urinary Metabolic Phenotype-Dependent Screening of Early and Small Hepatocellular Carcinoma.
- Hepatobiliary-Phase Hypointense Nodules Without Arterial-Phase Hyperenhancement: Developing a Risk Stratification for Hypervascular Transformation Based on a Real-World Observational Cohort Study.
- Identification of SGMS2 as a molecule involved in natural killer cell recruitment and its in-deep analysis in the liver cancer microenvironment: Evidence from large populations cohort.
- Response Evaluation Using Contrast-Enhanced Ultrasound for Unresectable Advanced Hepatocellular Carcinoma Treated With Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy.
- Impact of Hepatocellular Carcinoma Tumor Size on Sonazoid Contrast-Enhanced Ultrasound Enhancement Features.
- Exosomal microRNAs in hepatocellular carcinoma, expanding research field.
- Laser-Induced Combinatorial Chemotherapeutic, Chemodynamic, and Photothermal Therapy for Hepatocellular Carcinoma Based on Oxaliplatin-Loaded Metal-Organic Frameworks.
- Preoperative identification of cytokeratin 19 status of hepatocellular carcinoma based on diffusion kurtosis imaging.
- Subcentimeter hepatocellular carcinoma (HCC) on gadoxetic-acid-enhanced MRI: less frequent typical imaging features compared to 1-2 cm HCC but better prognosis after surgical resection.
- Combined early dynamic 18F-FDG PET/CT and conventional whole-body 18F-FDG PET/CT in hepatocellular carcinoma.
- The added value of 18F-FDG PET/MRI multimodal imaging in hepatocellular carcinoma for identifying cytokeratin 19 status.
- Distinct radiological features of lymphoepithelioma-like intrahepatic cholangiocarcinoma: comparison with classical intrahepatic cholangiocarcinoma.
- Non-invasive imaging in the diagnosis of combined hepatocellular carcinoma and cholangiocarcinoma.
- Radiomics on Gadoxetate Disodium-enhanced MRI: Non-invasively Identifying Glypican 3-Positive Hepatocellular Carcinoma and Postoperative Recurrence.
- Preoperatively Identify the Microvascular Invasion of Hepatocellular Carcinoma with the Restricted Spectrum Imaging.
- Diagnostic performance of gadoxetic acid-enhanced abbreviated magnetic resonance imaging protocol in small hepatocellular carcinoma (≤2 cm) in high-risk patients.
- Synergistic Photochemo Effects Based on Light-Activatable Dual Prodrug Nanoparticles for Effective Cancer Therapy.
- Novel Three-Dimensional Hierarchical Porous Carbon Probe for the Discovery of N-Glycan Biomarkers and Early Hepatocellular Carcinoma Detection.
- Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma.
- Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma.
- Radiographic and α-fetoprotein response predict pathologic complete response to immunotherapy plus a TKI in hepatocellular carcinoma: a multicenter study.
- The prognostic role of the AST/ALT ratio in hepatocellular carcinoma patients receiving thermal ablation combined with simultaneous TACE.
- Inhibition of autophagy in macrophage promotes IL-1β-mediated hepatocellular carcinoma progression via inflammasome accumulation and self-recruitment.
- Ferroptosis in hepatocellular carcinoma: mechanisms and targeted therapy.
- HSF1 is involved in immunotherapeutic response through regulating APOJ/STAT3-mediated PD-L1 expression in hepatocellular carcinoma.
- WDR4/TRIM28 is a novel molecular target linked to lenvatinib resistance that helps retain the stem characteristics in hepatocellular carcinomas.
- Oncogenic miR-93-5p/Gal-9 axis drives CD8 (+) T-cell inactivation and is a therapeutic target for hepatocellular carcinoma immunotherapy.
- Effectiveness and safety of lenvatinib plus anti-programmed death-1 antibodies in patients with hepatocellular carcinoma: A real-world cohort study.
- GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy.
- The deubiquitinating enzyme USP44 suppresses hepatocellular carcinoma progression by inhibiting Hedgehog signaling and PDL1 expression.
- Loss of 5-hydroxymethylcytosine induces chemotherapy resistance in hepatocellular carcinoma via the 5-hmC/PCAF/AKT axis.
- Oxaliplatin-Resistant Hepatocellular Carcinoma Drives Immune Evasion Through PD-L1 Up-Regulation and PMN-Singular Recruitment.
- Genomic and transcriptomic profiling reveals key molecules in metastatic potentials and organ-tropisms of hepatocellular carcinoma.
- Gas7 attenuates hepatocellular carcinoma progression and chemoresistance through the PI3K/Akt signaling pathway.
- Portal vein tumor thrombosis in hepatocellular carcinoma: molecular mechanism and therapy.
- Combining γ-GT, PIVKA-II, and AFP to predict long-term prognosis in patients with hepatocellular carcinoma after hepatectomy.
- Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective.
- Clinical application of preoperative shear wave dispersion for prediction of post liver failure in patients with hepatocellular carcinoma after hepatectomy.
- Clinical application of two dimensional shear wave elastography with a propagation map in evaluating liver fibrosis in patients with liver tumors.
- MAIT cells confer resistance to Lenvatinib plus anti-PD1 antibodies in hepatocellular carcinoma through TNF-TNFRSF1B pathway.
- Quantitative image features of gadoxetic acid-enhanced MRI for predicting glypican-3 expression of small hepatocellular carcinoma ≤3 cm.
- Single-cell and spatial architecture of primary liver cancer.
- An improved diagnostic algorithm for subcentimeter hepatocellular carcinoma on gadoxetic acid-enhanced MRI.
- Combined hepatocellular carcinoma-cholangiocarcinoma with a predominant HCC component: better survival and MRI-based prediction.
- Preoperative transarterial chemoembolization with drug-eluting beads (DEB-TACE) in patients undergoing conversional hepatectomy: a propensity-score matching analysis.
- Prognostic value of LI-RADS category on MRI in patients with primary hepatic lymphoepithelioma-like carcinoma.
- Prognostic factors for long-term outcome in bifocal hepatocellular carcinoma after resection.
- Glycoproteomic contributions to hepatocellular carcinoma research: a 2023 update.
- The Pyroptosis-Related Signature Composed of GSDMC Predicts Prognosis and Contributes to Growth and Metastasis of Hepatocellular Carcinoma.
- Sublethal heat treatment enhances lactic acid uptake in macrophages via MCT1, leading to reduced paraspeckle formation and a subsequent decrease in macrophage pyroptosis.
- Prognostic model for predicting outcome and guiding treatment decision for unresectable hepatocellular carcinoma treated with lenvatinib monotherapy or lenvatinib plus immunotherapy.
- Disruption of SLFN11 Deficiency-Induced CCL2 Signaling and Macrophage M2 Polarization Potentiates Anti-PD-1 Therapy Efficacy in Hepatocellular Carcinoma.
- Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack.
- Disrupted BRCA1-PALB2 interaction induces tumor immunosuppression and T-lymphocyte infiltration in HCC through cGAS-STING pathway.
- Ten-eleven translocation-2 inactivation restrains IL-10-producing regulatory B cells to enable antitumor immunity in hepatocellular carcinoma.
- Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA.
- Synthetic miR-26a mimics delivered by tumor exosomes repress hepatocellular carcinoma through downregulating lymphoid enhancer factor 1.
- Development of a deep pathomics score for predicting hepatocellular carcinoma recurrence after liver transplantation.
- Autophagy suppression facilitates macrophage M2 polarization via increased instability of NF-κB pathway in hepatocellular carcinoma.
- Intratumoral PPT1-positive macrophages determine immunosuppressive contexture and immunotherapy response in hepatocellular carcinoma.
- Prognosis of spontaneously ruptured hepatocellular carcinoma: a propensity score matching study.
- Increased expression of autophagy-related gene 5 indicates poor prognosis in patients with hepatocellular carcinoma.
- IRF5 promotes glycolysis in the progression of hepatocellular carcinoma and is regulated by TRIM35.
- Assessment of an MR Elastography-Based Nomogram as a Potential Imaging Biomarker for Predicting Microvascular Invasion of Hepatocellular Carcinoma.
- An MRI-Based Prognostic Stratification System for Medical Decision-Making of Multinodular Hepatocellular Carcinoma Patients Beyond the Milan Criteria.
- Characterization of Microvascular Invasion in Hepatocellular Carcinoma Using Computational Modeling of Interstitial Fluid Pressure and Velocity.
- Deciphering intratumoral heterogeneity of hepatocellular carcinoma with microvascular invasion with radiogenomic analysis.
- Predicting the recurrence of hepatocellular carcinoma (≤ 5 cm) after resection surgery with promising risk factors: habitat fraction of tumor and its peritumoral micro-environment.
- The significance of the predominant component in combined hepatocellular-cholangiocarcinoma: MRI manifestation and prognostic value.
- Preoperative assessment of microvascular invasion of hepatocellular carcinoma using non-Gaussian diffusion-weighted imaging with a fractional order calculus model: A pilot study.
- Prediction of therapeutic response of advanced hepatocellular carcinoma to combined targeted immunotherapy by MRI.
- Lactylome analysis suggests lactylation-dependent mechanisms of metabolic adaptation in hepatocellular carcinoma.
- Combination of Vitamin C and Lenvatinib potentiates antitumor effects in hepatocellular carcinoma cells in vitro.
- Preliminary radiogenomic study of hepatitis B virus-related hepatocellular carcinoma: associations between MRI features and mutations.
- The miR-34a-5p-c-MYC-CHK1/CHK2 Axis Counteracts Cancer Stem Cell-Like Properties and Enhances Radiosensitivity in Hepatocellular Cancer Through Repression of the DNA Damage Response.
- Perioperative and oncologic outcomes of laparoscopic versus open liver resection for combined hepatocellular-cholangiocarcinoma: a propensity score matching analysis.
- The Effects of Cinobufagin on Hepatocellular Carcinoma Cells Enhanced by MRT68921, an Autophagy Inhibitor.
- Secretome of senescent hepatic stellate cells favors malignant transformation from nonalcoholic steatohepatitis-fibrotic progression to hepatocellular carcinoma.
- Applications of Dynamic Contrast-Enhanced Ultrasound in Differential Diagnosis of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma in Non-cirrhotic Liver.
- Stereotactic body radiotherapy combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: A phase II clinical trial.
- Iridium Complex-Loaded Sorafenib Nanocomposites for Synergistic Chemo-photodynamic Therapy of Hepatocellular Carcinoma.
- Contrast-enhanced magnetic resonance imaging perfusion can predict microvascular invasion in patients with hepatocellular carcinoma (between 1 and 5 cm).
- MRI-based Nomogram Predicts the Risk of Progression of Unresectable Hepatocellular Carcinoma After Combined Lenvatinib and anti-PD-1 Antibody Therapy.
- Comprehensive analysis of complement-associated molecular features in hepatocellular carcinoma.
- TMEM106A transcriptionally regulated by promoter methylation is involved in invasion and metastasis of hepatocellular carcinoma.
- Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis.
- Hepatobiliary phase images of gadoxetic acid-enhanced MRI may improve accuracy of predicting the size of hepatocellular carcinoma at pathology.
- Antiviral therapy improves postoperative survival of patients with HBV-related hepatocellular carcinoma.
- Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study.
- Nonviral mcDNA-mediated bispecific CAR T cells kill tumor cells in an experimental mouse model of hepatocellular carcinoma.
- Exosomal microRNAs in the DLK1-DIO3 imprinted region derived from cancer-associated fibroblasts promote progression of hepatocellular carcinoma by targeting hedgehog interacting protein.
- A novel prognostic model for hepatocellular carcinoma based on 5 microRNAs related to vascular invasion.
- Tumor-derived PD1 and PD-L1 could promote hepatocellular carcinoma growth through autophagy induction in vitro.
- Understanding initiation and progression of hepatocellular carcinoma through single cell sequencing.
- Prediction of programmed cell death protein 1 in hepatocellular carcinoma patients using radiomics analysis with radiofrequency-based ultrasound multifeature maps.
- The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study.
- Peripheral naïve CD8+ T cells as a predictive biomarker of response to lenvatinib plus an anti-PD-1 antibody in advanced hepatocellular carcinoma: a biomarker study.
- IFNα Potentiates Anti-PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment.
- CD74+ macrophages are associated with favorable prognosis and immune contexture in hepatocellular carcinoma.
- MTDH antisense oligonucleotides reshape the immunosuppressive tumor microenvironment to sensitize Hepatocellular Carcinoma to immune checkpoint blockade therapy.
- CircRPN2 Inhibits Aerobic Glycolysis and Metastasis in Hepatocellular Carcinoma.
- The spatial distribution of immune cell subpopulations in hepatocellular carcinoma.
- Targeting HNRNPM Inhibits Cancer Stemness and Enhances Antitumor Immunity in Wnt-activated Hepatocellular Carcinoma.
- The LINC00152/miR-205-5p/CXCL11 axis in hepatocellular carcinoma cancer-associated fibroblasts affects cancer cell phenotypes and tumor growth.
- CD155/SRC complex promotes hepatocellular carcinoma progression via inhibiting the p38 MAPK signalling pathway and correlates with poor prognosis.
- Preoperative prediction of microvascular invasion (MVI) in hepatocellular carcinoma based on kupffer phase radiomics features of sonazoid contrast-enhanced ultrasound (SCEUS): A prospective study.
- Baseline and contrast-enhanced ultrasound features of hepatic epithelioid angiomyolipoma.
- Hepatocellular carcinoma in the non-cirrhotic liver.
- CT volumetry helps predict prognosis of large hepatocellular carcinoma after resection.
- Microwave ablation combined with lipiodol-microsphere mixed or conventional transarterial chemoembolization for the treatment of colorectal liver metastases: A retrospective study.
- An Immune-Related Gene Signature Predicting Prognosis and Immunotherapy Response in Hepatocellular Carcinoma.
- First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review.
- Prognostic Significance of Tumor Growth Rate (TGR) in Patients with Huge Hepatocellular Carcinoma Undergoing Transcatheter Arterial Chemoembolization.
- BRG1 regulates lipid metabolism in hepatocellular carcinoma through the PIK3AP1/PI3K/AKT pathway by mediating GLMP expression.
- Development of a Costimulatory Molecule Signature to Predict Prognosis, Immune Landscape, and Response to Immune Therapy for Hepatocellular Carcinoma.
- Identification of Epithelial Mesenchymal Transition-Related lncRNAs Associated with Prognosis and Tumor Immune Microenvironment of Hepatocellular Carcinoma.
- Differentiating Cytokeratin 19 expression of hepatocellular carcinoma by using multi-b-value diffusion-weighted MR imaging with mono-exponential, stretched exponential, intravoxel incoherent motion, diffusion kurtosis imaging and fractional
- Combined hepatocellular carcinoma-cholangiocarcinoma: MRI features correlated with tumor biomarkers and prognosis.
- Histopathological components correlated with MRI features and prognosis in combined hepatocellular carcinoma-cholangiocarcinoma.
- Risk stratification of LI-RADS M and LI-RADS 4/5 combined hepatocellular cholangiocarcinoma: prognostic values of MR imaging features and clinicopathological factors.
- Contrast-enhanced MRI could predict response of systemic therapy in advanced intrahepatic cholangiocarcinoma.
- DCE-MRI based radiomics nomogram for preoperatively differentiating combined hepatocellular-cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma.
- Microvascular invasion of small hepatocellular carcinoma can be preoperatively predicted by the 3D quantification of MRI.
- Camrelizumab: an investigational agent for hepatocellular carcinoma.
- Microwave ablation and synchronous transarterial chemoembolization combined with PD-1 inhibitor in patients with hepatocellular carcinoma following tyrosine kinase inhibitor intolerance.
- Criteria for identifying potentially resectable patients with initially oncologically unresectable hepatocellular carcinoma before treatment with lenvatinib plus an anti-PD-1 antibody.
- Construction and Validation of an Epigenetic Regulator Signature as A Novel Biomarker For Prognosis, Immunotherapy, And Chemotherapy In Hepatocellular Carcinoma.
- Molecular Characteristics of T Cell-Mediated Tumor Killing in Hepatocellular Carcinoma.
- Comprehensive Analysis of HHLA2 as a Prognostic Biomarker and Its Association With Immune Infiltrates in Hepatocellular Carcinoma.
- Characteristics and Clinical Significance of T-Cell Receptor Repertoire in Hepatocellular Carcinoma.
- Gut microbiota modulate radiotherapy-associated antitumor immune responses against hepatocellular carcinoma Via STING signaling.
- Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics.
- Exosome-depleted MiR-148a-3p derived from Hepatic Stellate Cells Promotes Tumor Progression via ITGA5/PI3K/Akt Axis in Hepatocellular Carcinoma.
- Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation.
- The treatment strategy and outcome for spontaneously ruptured hepatocellular carcinoma: a single-center experience in 239 patients.
- Hsa_circ_0003945 promotes progression of hepatocellular carcinoma by mediating miR-34c-5p/LGR4/β-catenin axis activity.
- High serum soluble CD155 level predicts poor prognosis and correlates with an immunosuppressive tumor microenvironment in hepatocellular carcinoma.
- Tumor associated macrophages-derived exosomes facilitate hepatocellular carcinoma malignance by transferring lncMMPA to tumor cells and activating glycolysis pathway.
- PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma.
- PARG inhibition limits HCC progression and potentiates the efficacy of immune checkpoint therapy.
- A novel murine model of combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
- lncRNA-AC079061.1/VIPR1 axis may suppress the development of hepatocellular carcinoma: a bioinformatics analysis and experimental validation.
- GPM6A expression is suppressed in hepatocellular carcinoma through miRNA-96 production.
- The E3 ubiquitin ligase SOCS-7 reverses immunosuppression via Shc1 signaling in hepatocellular carcinoma.
- Changing epidemiology of hepatocellular carcinoma in Asia.
- Hepatic Arterial Infusion Chemotherapy with Oxaliplatin Plus Raltitrexed as an Alternative Option in Advanced Hepatocellular Carcinoma Patients with Failure of, or Unsuitability for, Transarterial Chemoembolization.
- Recurrence Outcome in Hepatocellular Carcinoma within Milan Criteria Undergoing Microwave Ablation with or without Transarterial Chemoembolization.
- Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study.
- Sphingosine-1-phosphate transporter spinster homolog 2 is essential for iron-regulated metastasis of hepatocellular carcinoma.
- An SCD1-dependent mechanoresponsive pathway promotes HCC invasion and metastasis through lipid metabolic reprogramming.
- Modulation of the p38 MAPK Pathway by Anisomycin Promotes Ferroptosis of Hepatocellular Carcinoma through Phosphorylation of H3S10.
- GTPBP4 promotes hepatocellular carcinoma progression and metastasis via the PKM2 dependent glucose metabolism.
- Whole-genome sequencing reveals the evolutionary trajectory of HBV-related hepatocellular carcinoma early recurrence.
- Increase of Portal Vein Pressure Gradient After Hepatectomy Predicts Post-operative Liver Dysfunction.
- Role of Plasma methylated SEPT9 for Predicting Microvascular Invasion and Tumor Proliferation in Hepatocellular Carcinoma.
- Future liver volume combined with platelet count predicts liver failure after major hepatectomy.
- ARHGAP24 represses β-catenin transactivation-induced invasiveness in hepatocellular carcinoma mainly by acting as a GTPase-independent scaffold.
- Contrast-Enhanced Ultrasound Features of Histopathologically Proven Hepatocellular Carcinoma in the Non-cirrhotic Liver: A Multicenter Study.
- Prediction of Microvascular Invasion in Combined Hepatocellular-Cholangiocarcinoma Based on Pre-operative Clinical Data and Contrast-Enhanced Ultrasound Characteristics.
- An mALBI-Child-Pugh-based nomogram for predicting post-hepatectomy liver failure grade B-C in patients with huge hepatocellular carcinoma: a multi-institutional study.
- Deep-learning-based analysis of preoperative MRI predicts microvascular invasion and outcome in hepatocellular carcinoma.
- Comparative study of evaluating the microcirculatory function status of primary small HCC between the CE (DCE-MRI) and Non-CE (IVIM-DWI) MR Perfusion Imaging.
- Investigating the value of pre-treatment 18F-FDG PET/CT in predicting the pathological characteristic of hepatocellular carcinoma and recurrence after liver transplantation.
- Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization.
- Characterization of immune infiltration in sarcomatoid hepatocellular carcinoma.
- Serum lnc34a is a potential prediction biomarker for bone metastasis in hepatocellular carcinoma patients.
- METTL3/IGF2BP1/CD47 contributes to the sublethal heat treatment induced mesenchymal transition in HCC.
- The diagnostic value of plasma exosomal hsa_circ_0070396 for hepatocellular carcinoma.
- Novel aptasensor-based assay of sonic hedgehog ligand for detection of portal vein invasion of hepatocellular carcinoma.
- Differences between exhausted CD8+ T cells in hepatocellular carcinoma patients with and without uremia.
- Prognostic significance of preoperative systemic immune-inflammation index in combined hepatocellular-cholangiocarcinoma.
- Associations among the mutational landscape, immune microenvironment, and prognosis in Chinese patients with hepatocellular carcinoma.
- Neutrophils: Driving inflammation during the development of hepatocellular carcinoma.
- The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma.
- CircRNA UBAP2 serves as a sponge of miR-1294 to increase tumorigenesis in hepatocellular carcinoma through regulating c-Myc expression.
- Embolization of the Transhepatic Tract after Percutaneous Portal Vein Interventions: Single-Centre Retrospective Study Comparing n-butyl Cyanoacrylate Versus Coils.
- Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma.
- Cancer-associated fibroblast-derived CXCL11 modulates hepatocellular carcinoma cell migration and tumor metastasis through the circUBAP2/miR-4756/IFIT1/3 axis.
- Hedgehog Signaling, a Critical Pathway Governing the Development and Progression of Hepatocellular Carcinoma.
- DNA sensing and associated type 1 interferon signaling contributes to progression of radiation-induced liver injury.
- LINC01133 promotes hepatocellular carcinoma progression by sponging miR-199a-5p and activating annexin A2.
- Quantitative acetylome analysis reveals histone modifications that may predict prognosis in hepatitis B-related hepatocellular carcinoma.
- AMD1 upregulates hepatocellular carcinoma cells stemness by FTO mediated mRNA demethylation.
- Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically.
- Differentiation between hepatocellular carcinoma and intrahepatic cholangiocarcinoma using contrast-enhanced ultrasound: A systematic review and meta-analysis.
- Early evaluation of treatment response to transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The role of dynamic three-dimensional contrast-enhanced ultrasound.
- Potential application of dynamic contrast enhanced ultrasound in predicting microvascular invasion of hepatocellular carcinoma.
- Imaging findings of fibrolamellar hepatocellular carcinomas on ultrasonography: A comparison with conventional hepatocellular carcinomas.
- Current Opinion about Hepatocellular Carcinoma <10 mm.
- The Prognostic Value of the Albumin to Gamma-Glutamyltransferase Ratio in Patients with Hepatocellular Carcinoma Undergoing Radiofrequency Ablation.
- The pathological significance of LOXL2 in pre-metastatic niche formation of HCC and its related molecular mechanism.
- Magnetic resonance imaging and diffusion-weighted imaging-based histogram analyses in predicting glypican 3-positive hepatocellular carcinoma.
- Feasibility of compressed sensing technique for isotropic dynamic contrast-enhanced liver magnetic resonance imaging.
- Prognostic nomograms and risk classifications of outcomes in very early-stage hepatocellular carcinoma patients after hepatectomy.
- Multi-scale and multi-parametric radiomics of gadoxetate disodium-enhanced MRI predicts microvascular invasion and outcome in patients with solitary hepatocellular carcinoma ≤ 5 cm.
- Serum LAG-3 Predicts Outcome and Treatment Response in Hepatocellular Carcinoma Patients With Transarterial Chemoembolization.
- AAV3-miRNA vectors for growth suppression of human hepatocellular carcinoma cells in vitro and human liver tumors in a murine xenograft model in vivo.
- The mRNA-miRNA-lncRNA Regulatory Network and Factors Associated with Prognosis Prediction of Hepatocellular Carcinoma.
- Exploring prognostic indicators in the pathological images of hepatocellular carcinoma based on deep learning.
- Do the existing staging systems for primary liver cancer apply to combined hepatocellular carcinoma-intrahepatic cholangiocarcinoma?
- Sintilimab plus sorafenib: a novel regimen for hepatocellular carcinoma.
- Albumin-to-alkaline phosphatase ratio as a predictor of tumor recurrence and prognosis in patients with early-stage hepatocellular carcinoma undergoing radiofrequency ablation as initial therapy.
- Cystathionine β-synthase mediated PRRX2/IL-6/STAT3 inactivation suppresses Tregs infiltration and induces apoptosis to inhibit HCC carcinogenesis.
- Comparing the efficacy and safety of local-regional treatments for hepatocellular carcinoma with portal/hepatic vein tumor thrombosis in China: a network meta-analysis of randomized controlled trials.
- Which is the best combination of surgery for hepatocellular carcinoma with hepatic/portal vein thrombosis in China: a network meta-analysis of randomized controlled trials.
- Using deep learning to predict microvascular invasion in hepatocellular carcinoma based on dynamic contrast-enhanced MRI combined with clinical parameters.
- Hypoxia blocks ferroptosis of hepatocellular carcinoma via suppression of METTL14 triggered YTHDF2-dependent silencing of SLC7A11.
- Down-regulation of EOMES drives T-cell exhaustion via abolishing EOMES-mediated repression of inhibitory receptors of T cells in liver cancer.
- Sulfarotene, a synthetic retinoid, overcomes stemness and sorafenib resistance of hepatocellular carcinoma via suppressing SOS2-RAS pathway.
- A New Scoring Method for Personalized Prognostic Prediction in Patients with Combined Hepatocellular and Cholangiocarcinoma After Surgery.
- Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma.
- Hepatic NOD2 promotes hepatocarcinogenesis via a RIP2-mediated proinflammatory response and a novel nuclear autophagy-mediated DNA damage mechanism.
- Tumor cell-imposed iron restriction drives immunosuppressive polarization of tumor-associated macrophages.
- The Diagnostic Performance of lncRNAs from Blood Specimens in Patients with Hepatocellular Carcinoma: A Meta-Analysis.
- MNS1 promotes hepatocarcinogenesis and metastasis via activating PI3K/AKT by translocating β-catenin and predicts poor prognosis.
- Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation.
- CircMEMO1 modulates the promoter methylation and expression of TCF21 to regulate hepatocellular carcinoma progression and sorafenib treatment sensitivity.
- Circulating tumor cell detection and single-cell analysis using an integrated workflow based on ChimeraX® -i120 Platform: A prospective study.
- WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression.
- Laparoscopic hepatectomy enhances recovery for small hepatocellular carcinoma with liver cirrhosis by postoperative inflammatory response attenuation: a propensity score matching analysis with a conventional open approach.
- Matrix stiffness-mediated effects on macrophages polarization and their LOXL2 expression.
- The prognostic significance of microRNA-221 in hepatocellular carcinoma: An updated meta-analysis.
- Rare submandibular gland metastasis of hepatocellular carcinoma: case report and review of the literature.
- Sintilimab plus IBI305 for hepatocellular carcinoma - Author's reply.
- Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Chinese-language papers (not in the count)3
- [Chinese expert guidance on overall application of lenvatinib in hepatocellular carcinoma].
- [Advances in imaging diagnosis of mixed-type liver cancer].
- [Study of magnetic resonance imaging based on liver imaging reporting and data system for evaluating phosphatidylinositol proteoglycan-3 expression in hepatocellular carcinoma].
All its trials on ClinicalTrials.gov, any status155
- The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
- Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study
- NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC
- A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer
- Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
- Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC
- Biomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion Therapy
- Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy
- IL1RAP-targeting Chimeric Antigen Receptor T Cells in the Treatment of Relapsed/Refractory Hepatocellular Carcinoma
- Therapeutic Effects of Immuno-targeted Therapy Combined With or Without RT for HCC
- Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC
- Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma
- Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors
- Impact of Preoperative Serum Albumin Level on Postoperative Outcomes in Chinese HCC Patients Treated With Surgery
- Effect of TCC Cocktail Combined With TACE Versus TACE Alone on Survival in uHCC Patients
- Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage Hepatocellular Carcinoma
- Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer
- M-TACE Treatment for Unresectable Hepatocellular Carcinoma
- A Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCC
- A Single Center Real-world Study of Donafenib in the Treatment of Hepatocellular Carcinoma in Routine Clinical Practice
- Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma
- A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC
- Treatment of Avatrombopag for Thrombocytopenia in Patients Undergoing Selective Resection of Hepatocellular Carcinoma
- Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT
- Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma
- Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC
- Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC
- TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma
- Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC
- Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients
- Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.
- Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC
- A Survey for Factors That Influence Postoperative Treatment Decision-making for Hepatocellular Carcinoma
- Establishment of Molecular Classification Models for Early Diagnosis of Digestive System Cancers
- A Prospective, Randomized, Multicenter Study of Comparison of TACE Combination With and Without EBRT for Hepatocellular Carcinoma With Portal Vein Tumor Thrombi
- Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular Carcinoma
- Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma
- Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients With Hepatocellular Carcinoma
- Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma
- SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma
- Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant
- A Study of Individualized Radiotherapy Based on a Prediction Model of Lymph Node Metastasis in Hepatocellular Carcinoma
- Adjuvant Therapy With Anlotinib for HCC
- Study on Recurrence Monitoring of Hepatocellular Carcinoma With 5-Hydroxymethylcytosine Test
- SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery
- Adjuvant Therapy With Apatinib for HCC Patients With PVTT Who Underwent Radical Resection
- Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus
- A Study of Comparison of TACE Combination With and Without EBRT for Advanced HCC
- Effect of Enhanced Recovery After Surgery(ERAS) After Liver Resection for Primary Liver Cancer
- TACE Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular Carcinoma
- Combination Treatment for Advanced Liver Cancer
- Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma
- A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma
- TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment
- Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
- HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
- Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
- Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
- Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment
- Hepatic Artery Infusion Chemotherapy for Unresectable Hepatocelluar Carcinoma Who Failed to Systemic Therapy
- cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria
- Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
- Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation
- Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection
- Adjuvant IFN-α for Patients Underwent Curative Surgery for HCC With a Low miR-26 Expression
- TACE as an Adjuvant Therapy After Hepatectomy for HCC
- Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy
- Sirolimus-Based Immunosuppression Therapy in OLT for Patients With HCC Exceeding Milan Criteria
- Study of Thymopentin in Patients After Curative Resection of Small Hepatocellular Carcinoma
- Capecitabine to Prevent Recurrence of Hepatocellular Carcinoma After Curative Resection
- Effect of Target Therapy on Patients Undergoing Synchronic Hepatectomy for Colorectal Liver Metastases
- Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads
- First in Human Study of SIM0610 in Solid Tumors
- Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
- A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
- A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma
- A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
- A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma
- JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer
- Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs
- A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
- A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
- A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
- A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma
- MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
- 29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
- JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
- ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
- Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors
- A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
- CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
- A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
- A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
- Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
- Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
- Hepatocellular Carcinoma 3 Gene Methylation Combination Detection Kit (PCR Fluorescent Probe Method) Multicenter Clinical Trial
- Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
- A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)
- A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)
- A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization
- Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma
- A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
- Clinical Research on Dynamic Monitoring MRD Via Plasma ctDNA After Systemic Therapy of Hepatocellular Carcinoma
- BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma
- A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
- A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC
- A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
- A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
- A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC
- A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
- Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC
- A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev
- A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
- Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
- Efficacy and Safety of IBI310 Combined with Sintilimab in Patients with Advanced Hepatocellular Carcinoma
- To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer
- A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
- A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
- AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma
- A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
- Chimeric Antigen Receptor T Cells Targeting Glypican-3
- Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
- Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma
- Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection
- Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC)
- A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
- Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma
- Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
- Study of BGB-A317 in Participants With Previously Treated Unresectable HCC
- A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
- Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)
- A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
- The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects
- Hepatocellular Carcinoma Registry in Asia: The INSIGHT Registry
- A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC
- STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma
- HepaSphere Chemoembolization in Advanced HCC Patients: Safety & Efficacy Registry in China
- Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)
- A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma
- Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)
- Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma
- Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
- Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC
- Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC
- the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma
- Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) Patients
- A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection
- Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma
- Urea Cream Treatment Sorafenib-Associated HSFR in HCC
- T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients
Cancer
Stomach cancer
胃癌Led 134 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 1.4%.
18 hospitals in Shanghai for stomach cancer218 hospitals in China for stomach cancer
Open trials with this hospital 20
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Phase
- Phase 1
- Started
- 2025-10
- Registry
- NCT07213791
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingSynergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06468280
Age 18 years to 79 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingIMmune Proteomics to Predict neoAdjuvant Chemotherapy and immunoTherapy Response in Gastric Cancer
- Phase
- Not given
- Started
- 2024-08
- Registry
- NCT06662110
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingDetection of Peritoneal Metastasis of Gastric Cancer by Liquid Biopsy in Peripheral Blood: A Prospective Study
- Phase
- Not given
- Started
- 2022-03
- Registry
- NCT05347524
Age 18 years to 74 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingMulticenter Study on Laparoscopic Total Gastrectomy for Advanced Gastric Cancer
- Phase
- N/A
- Started
- 2021-01
- Registry
- NCT04710758
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- Not yet recruitingA Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Registry
- NCT07333573
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- Not yet recruitingFeasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment
- Phase
- Phase 3
- Started
- 2026-06
- Registry
- NCT07508956
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- Not yet recruitingFeasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS)
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07257380
Age 18 years to 79 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingClinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07385703
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou
- RecruitingSymbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2026-05
- Registry
- NCT07392892
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChengdu, Guangzhou, Shanghai, Wuhan
- RecruitingPhase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07700979
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shanghai
- RecruitingA Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Phase
- Phase 2
- Started
- 2025-02
- Registry
- NCT06760819
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Shanghai
- RecruitingReal-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- Phase
- Not given
- Started
- 2025-02
- Registry
- NCT06846996
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou
- RecruitingSON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2025-02
- Registry
- NCT06873659
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Jinan, Lanzhou, Nanjing, Shanghai, Xi'an
- RecruitingA Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
- Phase
- Phase 3
- Started
- 2025-08
- Registry
- NCT07023315
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Harbin, Shanghai, Shijiazhuang
- RecruitingA Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-07
- Registry
- NCT07066657
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changsha, Chongqing, Hangzhou, Harbin, Shanghai, Wuhan, Zhengzhou
- RecruitingRCT of EFTR Versus STER for GIST Treatment
- Phase
- N/A
- Started
- 2025-02
- Registry
- NCT07411118
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Phase 2 Clinical Study of ABSK061 and ABSK043
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06632262
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChengdu, Guiyang, Hangzhou, Harbin, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Xuzhou, Zhengzhou
- RecruitingPh1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer
- Phase
- Phase 2
- Started
- 2023-03
- Registry
- NCT05671822
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingStudy of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2021-06
- Registry
- NCT04900818
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Hefei, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led134
- Photo-triggered engineered microbes achieving dual epigenetic immunomodulation for gastric cancer.
- Feasibility and Safety of Endoscopic Full-Thickness Resection for Gastric Submucosal Tumors With Extraluminal Growth.
- Synergistic effects of PD-1 antibody and chemotherapy followed by surgery-centric local treatment in patients with limited-metastatic gastric or gastroesophageal adenocarcinoma (ROSETTE trial): an open-label, single-center, randomized phase
- Premature death patterns and trends of stomach cancer in Pudong, Shanghai: a population based study.
- Phosphorylation of MSX1 controls tumorigenesis and bone development through targeting FBXW7 degradation.
- TREM2 facilitates gastric cancer progression and immune evasion via inhibiting TRIM21-mediated STAT1 degradation in tumor-associated macrophages.
- Oxidative stress and Kras mutation in Mist1+ cells act in a double-hit manner to drive gastric tumorigenesis.
- Cancer-associated fibroblast miR-148a-5p/CALD1/collagen VI pathway promotes proliferation in Helicobacter pylori-positive gastric cancer.
- 18 F-FDG Versus 68 Ga-FAPI PET/MRI Findings in a Case of Primary Gastric Melanoma.
- Efficacy and safety of endoscopic intraperitoneal subserosal dissection for gastric submucosal tumors with extraluminal growth pattern.
- EPDR1 promotes gastric cancer progression via STAT3-mediated fatty acid metabolic reprogramming.
- Relationship between [18F]FDG PET/CT findings and claudin 18.2 expression in metastatic gastric cancer.
- m6A transferase KIAA1429 mediates the upregulation of LncRNA LINC00968 promoting the progression of gastric cancer cells.
- T-cell activation enhances anti-HER2-mediated antibody-dependent cellular cytotoxicity in gastric cancer.
- SYT4 Interacts with PSMC6 to Facilitate Malignant Progression in Gastric Carcinoma via Activating Wnt/β-catenin Signaling.
- Mechanistic insights into PD-1 inhibitor-associated immune thrombocytopenia: a case report integrating longitudinal transcriptomic profiling.
- Blockade of CLEVER-1 restrains immune evasion and enhances anti-PD-1 immunotherapy in gastric cancer.
- Nutritional support after hospital discharge reduces long-term mortality in patients after gastric cancer surgery: Secondary analysis of a prospective randomized trial.
- Spatiotemporal multi-omics analysis uncovers NAD-dependent immunosuppressive niche triggering early gastric cancer.
- Efficacy and safety of endoscopic submucosal dissection for pyloric neoplasms.
- Feasibility and safety of endoscopic resection for cardial submucosal tumors more than 30 mm in diameter.
- Zipper endoscopic full-thickness resection: a pilot study in subepithelial tumor management (with video).
- Multi-omics integration reveals gut Microbiome and Short-chain fatty acid profiles in gastric cancer cachexia patients and their clinical significance.
- High-Throughput Metabolic Pattern Screening Strategy for Early Colorectal and Gastric Cancers Based on Covalent Organic Frameworks-Assisted Laser Desorption/Ionization Mass Spectrometry.
- An experience of laparoscopic-assisted D2 radical gastrectomy with uncut Roux-en-Y anastomosis for distal gastric cancer.
- Modeling human gastric cancers in immunocompetent mice.
- Road of no return - loss of TP53 paves a defined evolution path from gastric preneoplasia-to-cancer.
- Transarterial Infusion Chemotherapy and Embolization for Patients With Unresectable Advanced Cancer of Stomach or Gastroesophageal Junction: A Retrospective Study.
- Safety, effectiveness and the optimal duration of preoperative imatinib in locally advanced gastric gastrointestinal stromal tumors: A retrospective cohort study.
- IL-4/IL-4R axis signaling drives resistance to immunotherapy by inducing the upregulation of Fcγ receptor IIB in M2 macrophages.
- Ubiquilin-4 induces immune escape in gastric cancer by activating the notch signaling pathway.
- Blockade of V-domain immunoglobulin suppressor of T-cell activation reprograms tumour-associated macrophages and improves efficacy of PD-1 inhibitor in gastric cancer.
- Elevated 18F-FDG uptake in subcutaneous adipose tissue correlates negatively with nutritional status and prognostic survival in cachexia patients with gastric cancer.
- REST Promotes Autophagy in Gastric Cancer by Transcriptionally Activating FABP6 to Inhibit the Akt/mTOR Signaling Pathway.
- Amlodipine inhibits Synaptotagmin-4's oncogenic activity on gastric cancer proliferation by targeting calcium signaling.
- Automatically optimized radiomics modeling system for small gastric submucosal tumor (<2 cm) discrimination based on EUS images.
- New endoscopic closure technique, "internal traction-assisted suspended closure," for GI defect closure: a pilot study (with video).
- IKZF3 amplification predicts worse prognosis especially in intestinal-type gastric cancer.
- A scoring system to predict the technical difficulty of endoscopic resection for cardial submucosal tumors.
- Pathologic Complete Response After Gastric Artery Chemoembolization Combined With Tislelizumab for Neoadjuvant Therapy of Locally Advanced Gastric Cancer: A Case Report.
- Circular RNA LDLRAD3 promotes gastric cancer progression by upregulating COL4A5 through sponging miR-h37.
- DeepRisk network: an AI-based tool for digital pathology signature and treatment responsiveness of gastric cancer using whole-slide images.
- Epstein-Barr virus infection upregulates extracellular OLFM4 to activate YAP signaling during gastric cancer progression.
- Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial.
- Early intravenous branched-chain amino acid-enriched nutrition supplementation in older patients undergoing gastric surgery: a randomized clinical trial.
- ScRNA-seq of gastric cancer tissues reveals differences in the immune microenvironment of primary tumors and metastases.
- Clinical outcomes of endoscopic resection for the treatment of intermediate- or high-risk gastric small gastrointestinal stromal tumors: a multicenter retrospective study.
- A cofactor-induced repressive type of transcription factor condensation can be induced by synthetic peptides to suppress tumorigenesis.
- Reactivating Hippo by drug compounds to suppress gastric cancer and enhance chemotherapy sensitivity.
- The alanyl-tRNA synthetase AARS1 moonlights as a lactyltransferase to promote YAP signaling in gastric cancer.
- Endoscopic features and treatments of gastric cystica profunda.
- Prognostic value of preoperative CT features for disease-free survival in patients with primary gastric gastrointestinal stromal tumors after resection.
- The largest lymph node defined response to neoadjuvant chemotherapy can predict long-term prognosis in locally advanced gastric cancer.
- JUNB mediates oxaliplatin resistance via the MAPK signaling pathway in gastric cancer by chromatin accessibility and transcriptomic analysis.
- The Hippo signaling pathway in gastric cancer.
- ASO Author Reflections: The Prognostic Value of Pathologic Complete Response After Neoadjuvant Chemotherapy in Gastric Cancer.
- Is Pathologic Complete Response a Good Predictor for the Long-Term, Clinical Outcome in Patients with Gastric Cancer After Neoadjuvant Chemotherapy? A Retrospective, Multi-institution Study in China.
- Does resection after neoadjuvant chemotherapy of docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? a multicenter, prospective cohort study (Neo-REGATTA).
- Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy.
- Identifying HER2 from serum-derived exosomes in advanced gastric cancer as a promising biomarker for assessing tissue HER2 status and predicting the efficacy of trastuzumab-based therapy.
- Phase I study of adjuvant chemotherapy with nab-paclitaxel and S-1 for stage III Lauren's diffuse-type gastric cancer after D2 resection (NORDICA study).
- Multiplex immune profiling reveals the role of serum immune proteomics in predicting response to preoperative chemotherapy of gastric cancer.
- Single-cell RNA sequencing reveals the lineage of malignant epithelial cells and upregulation of TAGLN2 promotes peritoneal metastasis in gastric cancer.
- Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric Cancer.
- Endoscopic full-thickness resection, indication, methods and perspectives.
- Endoscopic removal of an extraluminal gastrointestinal stromal tumor recurrence located on the surgical stapler line at gastroesophageal junction.
- Immune landscape and prognostic gene signatures in gastric cancer: implications for cachexia and clinical outcomes.
- Submucosal Tunneling Techniques for Tumor Resection.
- CD36-BATF2\MYB Axis Predicts Anti-PD-1 Immunotherapy Response in Gastric Cancer.
- First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.
- Association of systemic inflammatory markers and tertiary lymphoid structure with pathological complete response in gastric cancer patients receiving preoperative treatment: a retrospective cohort study.
- Intraoperative Pathological Evaluation of Suspicious Peritoneal Nodules for Surgical Decision-making in Gastric Cancer.
- 124I-Labeled Immuno-PET Targeting hTREM2 for the Diagnosis of Gastric Carcinoma.
- Multilevel proteomic analyses reveal molecular diversity between diffuse-type and intestinal-type gastric cancer.
- A YAP/TAZ-CD54 axis is required for CXCR2-CD44- tumor-specific neutrophils to suppress gastric cancer.
- Risk factors for complications and incomplete resection after endoscopic resection for duodenal submucosal tumors.
- Endoscopic resection and suturing methods for non-ampullary duodenal submucosal tumors: "mini-invasive" treatments that should never be underestimated.
- Clinical outcomes of endoscopic resection for the treatment of esophageal gastrointestinal stromal tumors: a ten-year experience from a large tertiary center in China.
- COLEC12 Promotes Tumor Progression and Is Correlated With Poor Prognosis in Gastric Cancer.
- Diagnostic and economic value of carcinoembryonic antigen, carbohydrate antigen 19-9, and carbohydrate antigen 72-4 in gastrointestinal cancers.
- Exosome Metabolic Patterns on Aptamer-Coupled Polymorphic Carbon for Precise Detection of Early Gastric Cancer.
- Latency-associated Peptide Identifies Immunoevasive Subtype Gastric Cancer With Poor Prognosis and Inferior Chemotherapeutic Responsiveness.
- Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
- Efficacy of AS versus SOX regimen as first-line chemotherapy for gastric cancer patients with peritoneal metastasis: a real-world study.
- Identification of metabolism-related genes for predicting peritoneal metastasis in patients with gastric cancer.
- TIM3+ cells in gastric cancer: clinical correlates and association with immune context.
- Intratumoral PD-1+CD8+ T cells associate poor clinical outcomes and adjuvant chemotherapeutic benefit in gastric cancer.
- Haemoglobin A1c and serum glucose levels and risk of gastric cancer: a systematic review and meta-analysis.
- Impact of intratumoural CD96 expression on clinical outcome and therapeutic benefit in gastric cancer.
- Reticulon 2 promotes gastric cancer metastasis via activating endoplasmic reticulum Ca2+ efflux-mediated ERK signalling.
- Ubiquitylation of cyclin C by HACE1 regulates cisplatin-associated sensitivity in gastric cancer.
- Dual block HER2 assessment increased HER2 immunohistochemistry positive rate in resected specimens of gastric cancer: a prospective multicenter clinical trial from China.
- Endoscopic intraperitoneal subserosal dissection combined with endoscopic ultrasonography-assisted location of an extraluminally growing stromal tumor.
- Management of an esophagopleural fistula after resection of giant submucosal tumor of the cardia.
- circBGN accelerates gastric cancer cell proliferation and invasion via activating IL6/STAT3 signaling pathway.
- RNA m5C regulator-mediated modification patterns and the cross-talk between tumor microenvironment infiltration in gastric cancer.
- Automatic captioning of early gastric cancer using magnification endoscopy with narrow-band imaging.
- Endoscopic resection of upper GI extraluminal tumors (with videos).
- Endoscopic submucosal dissection for gastric adenocarcinoma of the fundic gland type (chief cell predominate type): Four years' experience from a tertiary hospital.
- Targeting ZFP64/GAL-1 axis promotes therapeutic effect of nab-paclitaxel and reverses immunosuppressive microenvironment in gastric cancer.
- Predictors of the difficulty for endoscopic resection of gastric gastrointestinal stromal tumor and follow-up data.
- Comparison of safety and short-term outcomes between endoscopic and laparoscopic resections of gastric gastrointestinal stromal tumors with a diameter of 2-5 cm.
- IRF-2 inhibits cancer proliferation by promoting AMER-1 transcription in human gastric cancer.
- EXOC4 Promotes Diffuse-Type Gastric Cancer Metastasis via Activating FAK Signal.
- Targeting Infiltrating Myeloid Cells in Gastric Cancer Using a Pretargeted Imaging Strategy Based on Bio-Orthogonal Diels-Alder Click Chemistry and Comparison with 89Zr-Labeled Anti-CD11b Positron Emission Tomography Imaging.
- The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction.
- Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals new therapeutic strategies.
- Clinicopathologic features of gastric glomus tumor: A report of 15 cases and literature review.
- Synchronous three different types of stomach tumors on 18F-FDG PET/CT.
- Landscape of esophageal submucosal tunneling endoscopic resection-related adverse events in a standardized lexicon: a large volume of 1701 cases.
- Long-term prognosis of small gastric gastrointestinal stromal tumors with high histological grade: a longitudinal nested cohort study.
- SP70 is a potential biomarker to identify gastric fundic gland neoplasms.
- ASO Author Reflections: Optimization of Tumor Therapy for the Specific Immune Microenvironment of Gastric Cancer.
- Clinical Outcomes and Immune Metrics in Intratumoral Basophil-Enriched Gastric Cancer Patients.
- Stemness-related LncRNA pair signature for predicting therapy response in gastric cancer.
- G3BP1 interacts with YWHAZ to regulate chemoresistance and predict adjuvant chemotherapy benefit in gastric cancer.
- Intra-tumor metabolic heterogeneity of gastric cancer on 18F-FDG PETCT indicates patient survival outcomes.
- Subcutaneous, but not visceral, adipose tissue as a marker for prognosis in gastric cancer patients with cachexia.
- Reply letter to the editor-post-discharge oral nutritional supplements with dietary advice in patients at nutritional risk after surgery for gastric cancer: A randomized clinical trial.
- Post-discharge oral nutritional supplements with dietary advice in patients at nutritional risk after surgery for gastric cancer: A randomized clinical trial.
- BOP1 Silencing Suppresses Gastric Cancer Proliferation through p53 Modulation.
- Utility of preoperative computed tomography features in predicting the Ki-67 labeling index of gastric gastrointestinal stromal tumors.
- Tumor-derived LIF promotes chemoresistance via activating tumor-associated macrophages in gastric cancers.
- Identifying early gastric cancer under magnifying narrow-band images with deep learning: a multicenter study.
- Endoscopic transmural route for dissection of gastric submucosal tumors with extraluminal growth: experience in two cases.
- Submucosal tunneling endoscopic resection treatment of multiple gastrointestinal submucosal tumors.
- High Expression of TRIM15 Is Associated with Tumor Invasion and Predicts Poor Prognosis in Patients with Gastric Cancer.
- Reevaluation of lymphovascular invasion in gastric cancer using endothelial markers D2-40 and EVG: Enhanced detection, better predictor of lymph node metastasis and biological aggressiveness.
- Magnetic porous carbon-dependent platform for the determination of N-glycans from urine exosomes.
- Demethylation of the SFRP4 Promoter Drives Gastric Cancer Progression via the Wnt Pathway.
- HER2 promotes epithelial-mesenchymal transition through regulating osteopontin in gastric cancer.
- Improved submucosal tunneling endoscopic resection with slant tunnel for submucosal tumors in proximal esophagus.
- Controlled hypertension under hemostasis prevents post-gastric endoscopic submucosal dissection bleeding: a prospective randomized controlled trial.
- A novel nomogram based on cardia invasion and chemotherapy to predict postoperative overall survival of gastric cancer patients.
Chinese-language papers (not in the count)17
- [Clinicopathological characteristics and prognostic factors in 36 cases of early-stage gastric mixed adenoneuroendocrine carcinoma].
- [Clinical study on endoscopic resection of giant submucosal tumors in the esophagus or gastric cardia].
- [Clinicopathological features of gastric alpha-fetoprotein-producing adenocarcinoma with SWI/SNF complex deletion].
- [Analysis of risk factors for lymph node metastasis in 1096 patients with early gastric cancer and establishment of a predictive nomogram].
- [Clinicopathological features and prognosis of early-onset gastric cancer: a large-scale retrospective real-world study].
- [Trends, challenges, and reflections on early-onset gastric cancer].
- [Progress in the application of laparoscopic and endoscopic cooperative surgery in gastrointestinal stromal tumors].
- [Clinicopathological and molecular diagnostic features of early-onset gastric cancer: a study based on data from a single-center dedicated gastric cancer database].
- [A multicenter retrospective study on the efficacy of different anti-reflux reconstruction methods after proximal gastrectomy for gastric cancer].
- [Dilemmas in definition and classification of adenocarcinoma of esophagogastric junction: from history to current status].
- [Application value and difficulty analysis of fluorescence laparoscopy in lymphadenectomy of gastric cancer].
- [Advantages and disadvantages of transthoracic approach for adenocarcinoma of the esophagogastric junction].
- [Laparoscopic proximal gastrectomy and lymph node resection in adenocarcinoma of the esophagogastric junction].
- [The feasibility analysis of multi-slice spiral CT features of gastric stromal tumors in predicting pathological National Institutes of Health risk classification].
- [Clinicopathological features and survival analysis of gastric cancer patients with neuroendocrine differentiation after radical resection].
- [Interpretation of key points of Chinese expert consensus on function-preserving gastrectomy for gastric cancer (2021)].
- [Research progression in clinical treatment of gastric cancer in 2020].
All its trials on ClinicalTrials.gov, any status70
- Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment
- A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer
- Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS)
- Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer
- IMmune Proteomics to Predict neoAdjuvant Chemotherapy and immunoTherapy Response in Gastric Cancer
- Detection of Peritoneal Metastasis of Gastric Cancer by Liquid Biopsy in Peripheral Blood: A Prospective Study
- Multicenter Study on Laparoscopic Total Gastrectomy for Advanced Gastric Cancer
- Neoadjuvant TACiE in Locally Advanced Gastric Cancer
- A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma
- AssesSment of Early-deteCtion basEd oN liquiD Biopsy in GASTRIC Cancer, ASCEND-Gastric
- Establishment of Molecular Classification Models for Early Diagnosis of Digestive System Cancers
- Potential Clinical Utilities of Circulating Tumor DNA in Gastric Cancer
- Enriched-CRT 2017: Advanced Gastric Cancer With LN+ and LVI+, Chemotherapy vs. Chemoradiotherapy
- Study On Safety Of Laparoscopic Total Gastrectomy For Clinical Stage I Gastric Cancer
- Incidence of Pancreatic Fistula After Radical Gastrectomy
- Apatinib Plus XELOX as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
- To Observe the Efficacy and Safety by Comparing Chemotherapy(Docetaxel, Oxaliplatin Plus S1 ) Followed With Radical Resection Versus Chemotherapy Alone in Advanced Gastric Cancer With Single Non-curable Factor.
- A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer
- Assessing Her2/Neu Expression in Gastric Cancer With Dual or Multiple Tumor Tissue Paraffin Blocks
- Trastuzumab Based Therapy in HER2 Positive AGC
- Trial of Xeloda and Oxaliplatin (XELOX) as Neo-adjuvant Chemotherapy Followed by Surgery in Advanced Gastric Cancer Patients With Para-aortic Lymph Node Metastasis
- A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
- SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
- A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- RCT of EFTR Versus STER for GIST Treatment
- A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
- Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- A Phase 2 Clinical Study of ABSK061 and ABSK043
- Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer
- Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
- Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma
- Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
- Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer
- Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
- PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
- Consistency Between Treatment Responses in PDO Models and Clinical Outcomes in Gastric Cancer
- Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
- A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
- A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
- Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
- A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors
- A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis
- A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors
- A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
- Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
- Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
- Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers
- Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
- Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension
- Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer
- Telatinib Safety and Pharmacokinetics Study in China Patients With Advanced Solid Tumors
- A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer
- Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)
- Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer
- Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal Metastasis
- Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)
- Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma Surgery
- A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer
- A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
- Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)
- A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
Cancer
Hepatoblastoma
肝母细胞瘤Led 3 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 1.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Shanghai for hepatoblastoma88 hospitals in China for hepatoblastoma
No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- ACSL4 promotes the formation of the proliferative subtype in hepatoblastoma.
- YAP-activated NAT10 promotes hepatoblastoma progression by activating the pentose phosphate pathway.
- Modeling hepatoblastoma development with human fetal liver organoids reveals YAP1 activation is sufficient for tumorigenesis.
Cancer
Chordoma
脊索瘤Led no English-language PubMed papers on chordoma in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
15 hospitals in Shanghai for chordoma88 hospitals in China for chordoma
No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Cancer
Osteosarcoma
骨肉瘤Led 5 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
60 hospitals in Shanghai for osteosarcoma742 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led5
- Trifluoperazine activates AMPK / mTOR / ULK1 signaling pathway to induce mitophagy in osteosarcoma cells.
- Clinicopathological characteristics and genetic features of young and senior Ewing sarcoma patients.
- Establishment and characterization of a patient-derived metastatic extraskeletal Ewing sarcoma cell line ES-ZSS-1.
- miR-877-3p inhibits tumor growth and angiogenesis of osteosarcoma through fibroblast growth factor 2 signaling.
- Enhancement of anti-PD-1/PD-L1 immunotherapy for osteosarcoma using an intelligent autophagy-controlling metal organic framework.
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 28 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 5.3%.
- Open trials led
- 0
- recruiting or about to
21 hospitals in Shanghai for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingRCT of EFTR Versus STER for GIST Treatment
- Phase
- N/A
- Started
- 2025-02
- Registry
- NCT07411118
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led28
- The value of a nomogram model based on CT imaging features in differentiating duodenal gastrointestinal stromal tumors from pancreatic head neuroendocrine tumors.
- Endoscopic resection for small rectal gastrointestinal stromal tumors: a pilot study.
- A case of quadruple wild-type gastrointestinal stromal tumor with CDC42BPB::NTRK3 fusion and abundant lymphoid infiltration.
- Hidden risk factors for recurrence of jejunoileal Gastrointestinal stromal tumors with low NIH classification: implications for surveillance and adjuvant therapy.
- RNA profiling and immunohistochemistry analyses of circRNAs in imatinib-resistant gastrointestinal stromal tumors.
- Endoscopic treatment outcome of oesophageal gastrointestinal stromal tumours.
- Safety, effectiveness and the optimal duration of preoperative imatinib in locally advanced gastric gastrointestinal stromal tumors: A retrospective cohort study.
- A case report of abdominal metastatic dermatofibrosarcoma protuberans misdiagnosed as gastrointestinal stromal tumor.
- Proteomic Characterization Identifies Clinically Relevant Subgroups of Gastrointestinal Stromal Tumors.
- Automatically optimized radiomics modeling system for small gastric submucosal tumor (<2 cm) discrimination based on EUS images.
- Clinical outcomes of endoscopic resection for the treatment of intermediate- or high-risk gastric small gastrointestinal stromal tumors: a multicenter retrospective study.
- Prognostic value of preoperative CT features for disease-free survival in patients with primary gastric gastrointestinal stromal tumors after resection.
- Imatinib induces ferroptosis in gastrointestinal stromal tumors by promoting STUB1-mediated GPX4 ubiquitination.
- Endoscopic removal of an extraluminal gastrointestinal stromal tumor recurrence located on the surgical stapler line at gastroesophageal junction.
- New insight on the correlation of immune landscapes with immune markers expression in different risk classification of gastrointestinal stromal tumors.
- Endoscopic resection and suturing methods for non-ampullary duodenal submucosal tumors: "mini-invasive" treatments that should never be underestimated.
- Clinical outcomes of endoscopic resection for the treatment of esophageal gastrointestinal stromal tumors: a ten-year experience from a large tertiary center in China.
- THZ1 targeting CDK7 suppresses c-KIT transcriptional activity in gastrointestinal stromal tumours.
- Endoscopic intraperitoneal subserosal dissection combined with endoscopic ultrasonography-assisted location of an extraluminally growing stromal tumor.
- Comparison of safety and short-term outcomes between endoscopic and laparoscopic resections of gastric gastrointestinal stromal tumors with a diameter of 2-5 cm.
- Predictors of the difficulty for endoscopic resection of gastric gastrointestinal stromal tumor and follow-up data.
- A novel fusion between CDC42BPB and ALK in a patient with quadruple wild-type gastrointestinal stromal tumor.
- Clinicopathological and therapeutic analysis of PDGFRA mutated gastrointestinal stromal tumor.
- Long-term prognosis of small gastric gastrointestinal stromal tumors with high histological grade: a longitudinal nested cohort study.
- Utility of preoperative computed tomography features in predicting the Ki-67 labeling index of gastric gastrointestinal stromal tumors.
- Endoscopic transmural route for dissection of gastric submucosal tumors with extraluminal growth: experience in two cases.
- Immune Cell Infiltration and the Expression of PD-1 and PD-L1 in Primary PDGFRA-Mutant Gastrointestinal Stromal Tumors.
- BDNF expression in GISTs predicts poor prognosis when associated with PD-L1 positive tumor-infiltrating lymphocytes.
Chinese-language papers (not in the count)7
- [Reappraisals of biological behaviors of PDGFRA mutant gastrointestinal stromal tumor].
- [Clinicopathological features and prognostic factors of gastric intermediate-risk gastrointestinal stromal tumor after surgical resection: a retrospective study].
- [Clinical significance of pathological diagnosis and genetic abnormalities detection in gastrointestinal stromal tumor using endoscopic biopsy].
- [Progress in the application of laparoscopic and endoscopic cooperative surgery in gastrointestinal stromal tumors].
- [Research status and prospect of immunotherapy in gastrointestinal stromal tumors].
- [The feasibility analysis of multi-slice spiral CT features of gastric stromal tumors in predicting pathological National Institutes of Health risk classification].
- [Clinicopathological features and prognosis of gastrointestinal stromal tumors with KIT/PDGFRA gene "homozygous mutation": a multicenter retrospective cohort study].
Earlier papers (2016–2020)23
- Comparison of prognostic prediction models for rectal gastrointestinal stromal tumor.
- Upregulation of ZNF148 in SDHB-deficient gastrointestinal stromal tumor potentiates Forkhead box M1-mediated transcription and promotes tumor cell invasion.
- Clinical outcomes of different therapeutic modalities for rectal gastrointestinal stromal tumor: Summary of 14-year clinical experience in a single center.
- A Nomogram for Predicting Cancer-Specific Survival of Patients with Gastrointestinal Stromal Tumors.
- Tumor-associated tertiary lymphoid structure predicts postoperative outcomes in patients with primary gastrointestinal stromal tumors.
- Microscopic positive tumor margin does not increase the rate of recurrence in endoscopic resected gastric mesenchymal tumors compared to negative tumor margin.
- [The shift of the treatment strategy of gastrointestinal stromal tumor from the surgical perspective].
- [Research advance of liquid biopsy in gastrointestinal stromal tumors].
- [Clinicopathological features and prognosis of 59 patients with platelet-derived growth factor α-mutant gastrointestinal stromal tumor].
- [Retrospect of 2019: focus on the research progress of gastric neoplasm].
- Gastrointestinal stromal tumors (GISTs) with remarkable cystic change: a specific subtype of GISTs with relatively indolent behaviors and favorable prognoses.
- Clinicopathological Features and Prognosis of Small Gastric Gastrointestinal Stromal Tumors (GISTs).
- Endoscopic full-thickness resection (EFTR) without laparoscopic assistance for nonampullary duodenal subepithelial lesions: our clinical experience of 32 cases.
- Efficacy and safety of endoscopic resection for small submucosal tumors originating from the muscularis propria layer in the gastric fundus.
- [Research advances in the secondary resistance mechanism of imatinib in gastrointestinal stromal tumors].
- Submucosal tunnel endoscopic resection for extraluminal tumors: a novel endoscopic method for en bloc resection of predominant extraluminal growing subepithelial tumors or extra-gastrointestinal tumors (with videos).
- Incorporation of NLR into NIH stratification system increases predictive accuracy for surgically resected gastrointestinal stromal tumors.
- Long-term Outcomes of Submucosal Tunneling Endoscopic Resection for Upper Gastrointestinal Submucosal Tumors.
- A novel grasp-and-loop closure method for defect closure after endoscopic full-thickness resection (with video).
- Endoscopic Full-thickness Resection (EFTR) for Gastrointestinal Subepithelial Tumors.
- PIK3C2A is a gene-specific target of microRNA-518a-5p in imatinib mesylate-resistant gastrointestinal stromal tumor.
- RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor.
- Role of surgery in patients with focally progressive gastrointestinal stromal tumors resistant to imatinib.
All its trials on ClinicalTrials.gov, any status6
- Prospective Cohort Study of the Clinical Applications for the Pathologic Type, Staging, and Grading of GIST
- RCT of EFTR Versus STER for GIST Treatment
- Development and External Validation of a Prognostic Model for DFS After Curative Resection of Duodenal GIST
- A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
- A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor
- (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
Cancer
Neuroblastoma
神经母细胞瘤Led no English-language PubMed papers on neuroblastoma in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
34 hospitals in Shanghai for neuroblastoma352 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Cancer
Ewing sarcoma
尤文肉瘤Led 2 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 1.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
15 hospitals in Shanghai for Ewing sarcoma139 hospitals in China for Ewing sarcoma
No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Earlier papers (2016–2020)1
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 23 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 1.4%.
16 hospitals in Shanghai for multiple myeloma178 hospitals in China for multiple myeloma
Open trials with this hospital 13
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
- Phase
- Phase 2
- Started
- 2026-05
- Registry
- NCT07638683
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingIsatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
- Phase
- Not given
- Started
- 2026-06
- Registry
- NCT07663253
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan University; 9 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Kunming, Nanning, Nantong, Shanghai, Wuhan, Xi'an, Zhengzhou
- RecruitingThe China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study
- Phase
- Not given
- Started
- 2023-07
- Registry
- NCT05965115
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingLongitudinal Data Registry of Plasma Cell Dyscrasia
- Phase
- Not given
- Started
- 2023-03
- Registry
- NCT06760052
Age 19 years to 99 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingA Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Phase
- Phase 1
- Started
- 2026-05
- Registry
- NCT07477587
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou
- RecruitingCevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-06
- Registry
- NCT07555938
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesGuangzhou, Hangzhou, Jinan, Kunming, Nanjing, Qingdao, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan
- RecruitingA Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
- Phase
- Phase 3
- Started
- 2026-06
- Registry
- NCT07623798
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
- Phase
- Phase 1
- Started
- 2025-12
- Registry
- NCT07179679
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChengde, Chongqing, Guangzhou, Nanchang, Nanchong, Nanjing, Shanghai, Suzhou, Xi'an
- RecruitingA Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Registry
- NCT06083207
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Nanjing, Nanning, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an, Xuzhou
- RecruitingA Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma
- Phase
- Phase 1
- Started
- 2024-11
- Registry
- NCT06700395
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Shanghai
- RecruitingA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2021-09
- Registry
- NCT04973605
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chongqing, Fuzhou, Hangzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xiamen, Zhengzhou
- Not yet recruitingClinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-06
- Registry
- NCT07569757
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou
- Not yet recruitingA Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma
- Phase
- Phase 3
- Started
- 2025-04
- Registry
- NCT06895512
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led23
- LRP8-dependent cholesterol metabolism modulates mTORC1 signaling and apoptotic pathways in multiple myeloma.
- Myeloma cell-derived CXCL7 facilitates proliferation of tumor cells and occurrence of osteolytic lesions through JAK/STAT3 pathway.
- Real-World Data Analysis on Early Mortality in Chinese Multiple Myeloma Patients: Analysis of 1093 Patients During a 15-Year Period.
- NR5A2 (located on chromosome 1q32) inhibits ferroptosis and promotes drug resistance by regulating phospholipid remodeling in multiple myeloma.
- Light-chain amyloidosis with concomitant symptomatic myeloma (CRAB-SLiM features): clinical characteristics, cytogenetic abnormalities, and outcomes.
- The role of proliferating stem-like plasma cells in relapsed or refractory multiple myeloma: Insights from single-cell RNA sequencing and proteomic analysis.
- Detection of circulating plasma cells in peripheral blood using deep learning-based morphological analysis.
- Update on the outcome of M-protein screening program of multiple myeloma in China: A 7-year cohort study.
- IgE-kappa multiple myeloma with kappa free light chain: a case report.
- Real world outcomes of lenalidomide or bortezomib maintenance in patients with multiple myeloma not undergoing stem cell transplantation.
- PRUNE1 (located on chromosome 1q21.3) promotes multiple myeloma with 1q21 Gain by enhancing the links between purine and mitochondrion.
- Single-cell atlas of the immune microenvironment reveals macrophage reprogramming and the potential dual macrophage-targeted strategy in multiple myeloma.
- The prognostic role of 1q21 gain/amplification in newly diagnosed multiple myeloma: The faster, the worse.
- The loss of neoantigens is an important reason for immune escape in multiple myeloma patients with high intratumor heterogeneity.
- The obesity paradox in multiple myeloma: A report from Multiple Myeloma Research Foundation (MMRF) dataset.
- The evolving diagnosis and treatment paradigms of multiple myeloma in China: 15 years' experience of 1256 patients in a national medical center.
- Thrombosis events in Chinese patients with newly diagnosed multiple myeloma.
- A prognostic model incorporating inflammatory cells and cytokines for newly diagnosed multiple myeloma patients.
- Clinical profiles in multiple myeloma patients with extreme survivals: a study from a National Medical Center in China.
- Lenalidomide Promotes Thrombosis Formation, but Does Not Affect Platelet Activation in Multiple Myeloma.
- A Machine Learning Model to Predict Survival and Therapeutic Responses in Multiple Myeloma.
- The role of KIAA1191 in the necroptotic pathway of multiple myeloma.
- Bone marrow tracer uptake pattern of PET-CT in multiple myeloma: image interpretation and prognostic value.
Chinese-language papers (not in the count)3
- [Comparison of criteria for metabolically healthy overweight/obesity in Shanghai Changfeng study].
- [The efficacy and safety profile of ixazomib/lenalidomide/dexamethasone in relapsed/refractory multiple myeloma: a multicenter real-world study in China].
- [Progress of interleukin-6-related antibodies in the treatment of multiple myeloma].
All its trials on ClinicalTrials.gov, any status20
- Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
- A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
- Longitudinal Data Registry of Plasma Cell Dyscrasia
- The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study
- Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM
- A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
- Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
- A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma
- A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma
- A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
- A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects
- A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
- A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
- A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)
- A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
- Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
Blood disorders
Beta thalassaemia
β 地中海贫血Led 1 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
7 hospitals in Shanghai for beta thalassaemia157 hospitals in China for beta thalassaemia
No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Neuromyelitis optica spectrum disorder
视神经脊髓炎谱系疾病Led no English-language PubMed papers on neuromyelitis optica spectrum disorder in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
4 hospitals in Shanghai for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingProspective Cohort Study of Neuromyelitis Optica Spectrum Disorders (NMOSD)
- Phase
- Not given
- Started
- 2025-12
- Registry
- NCT07266051
Age 18 years to Not stated (registered criteria)
Led by Xiamen Hospital; 3 listed hospitals as study sitesShanghai, Xiamen
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
Other diseases
IgG4-related disease
IgG4相关性疾病Led 4 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 1.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Shanghai for IgG4-related disease46 hospitals in China for IgG4-related disease
No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led4
- Single-Cell RNA-Sequencing Reveals Peripheral T Helper Cells Promoting the Development of IgG4-Related Disease by Enhancing B Cell Activation and Differentiation.
- Clinical and pathological predictors of relapse in IgG4-related disease.
- Heart Transplantation for a Rare Case of Immunoglobulin G4-related Cardiac Pseudotumor.
- Prognostic factors in IgG4-related disease: a long-term monocentric Chinese cohort study.
More papers found outside PubMed (not counted)1
Other diseases
Myasthenia gravis
重症肌无力Led 1 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.2%.
- Open trials as a site
- 0
- led by another institution
7 hospitals in Shanghai for myasthenia gravis93 hospitals in China for myasthenia gravis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingEFG vs IVIG in TAMG
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07231523
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led no English-language PubMed papers on anti-NMDA receptor encephalitis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
9 hospitals in Shanghai for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis
No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Takayasu arteritis
大动脉炎Led 33 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 17.6%.
- Open trials as a site
- 0
- led by another institution
8 hospitals in Shanghai for Takayasu arteritis108 hospitals in China for Takayasu arteritis
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis
- Phase
- Phase 4
- Started
- 2024-06
- Registry
- NCT06498089
Age 18 years to 65 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingA Pilot Study in Severe Patients With Takayasu Arteritis.
- Phase
- Phase 4
- Started
- 2020-03
- Registry
- NCT04300686
Age 14 years to 100 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led33
- 2025 Chinese guideline for the imaging diagnosis and evaluation of Takayasu arteritis.
- A novel ultrasound-based score for assessing carotid artery activity in Takayasu's arteritis.
- Association of PET vascular activity score with Takayasu's arteritis angiographic progression.
- Bibliometric analysis and visualisation of research hotspots and frontiers in Takayasu's arteritis.
- Epidemiology of large vasculitis in Shanghai, China: A 10-year multicenter hospital-based study and systematic review.
- Pro-fibrotic effect of the susceptible gene PCSK5 in vascular fibrosis of Takayasu arteritis via TGF-β and SMAD3 signaling pathway activation.
- Comment on: Treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis. Reply.
- Treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis: an open-label study.
- High level of serum complement 3 is a risk factor for vascular stenosis progression in TA patients receiving tocilizumab: a prospective observational study.
- Exploration of molecular signatures associated with different clinical features of Takayasu arteritis based on a prospective cohort study.
- Associations of microcirculation damage on nailfold capillaroscopy with supra-aortic severe ischemic events in patients with Takayasu arteritis.
- An exploration of the feasibility and clinical value of half-dose 5-h total-body 18F-FDG PET/CT scan in patients with Takayasu arteritis.
- COVID-19 infection characteristics, risk factors and its potential impacts on Takayasu arteritis: a web-based survey in a large cohort.
- COVID-19 vaccine uptake, hesitancy and clinical effects on patients with Takayasu's arteritis: A web-based questionnaire survey from a large cohort.
- The role of plateletcrit in Takayasu arteritis: A potential biomarker for disease activity and 6-month treatment response.
- PET vascular activity score for predicting new angiographic lesions in patients with Takayasu arteritis: a Chinese cohort study.
- A novel molecular mechanism of vascular fibrosis in Takayasu arteritis: macrophage-derived GPNMB promoting adventitial fibroblast extracellular matrix production in the aorta.
- Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study.
- A comprehensive profile of chemokines in the peripheral blood and vascular tissue of patients with Takayasu arteritis.
- Efficacy and safety of tofacitinib versus leflunomide with glucocorticoids treatment in Takayasu arteritis: A prospective study.
- Transcatheter Aortic Valve Replacement for Aortic Regurgitation Caused by Takayasu Arteritis.
- Carotid Intima-media Thickness/Diameter Ratio and Peak Systolic Velocity as Risk Factors for Neurological Severe Ischemic Events in Takayasu Arteritis.
- Clinical characteristics, imaging phenotypes and events free survival in Takayasu arteritis patients with hypertension.
- Serum complement 3 is a potential biomarker for assessing disease activity in Takayasu arteritis.
- Curcumin alleviates inflammation in Takayasu's arteritis by blocking CCL2 overexpression in adventitial fibroblasts.
- The value of ultrasonography combined with clinical features for predicting carotid imaging progression of Takayasu's arteritis: a prospective cohort study.
- Risk assessment model for heart failure in Chinese patients with Takayasu's arteritis.
- Detection of mural inflammation with low b-value diffusion-weighted imaging in patients with active Takayasu Arteritis.
- Potential Role of Macrophage Phenotypes and CCL2 in the Pathogenesis of Takayasu Arteritis.
- Epidemiology of Takayasu arteritis in Shanghai: A hospital-based study and systematic review.
- Effectiveness and safety of tocilizumab in patients with refractory or severe Takayasu's arteritis: A prospective cohort study in a Chinese population.
- Effect of hydroxychloroquine on angiographic progression in routine treatment of Takayasu arteritis.
- Characteristics and Medium-term Outcomes of Takayasu Arteritis-related Renal Artery Stenosis: Analysis of a Large Chinese Cohort.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)22
- Involvement of the pulmonary arteries in patients with Takayasu arteritis: a prospective study from a single centre in China.
- Immunosuppression medication and cardiac function improvement treatments might prevent Takayasu arteritis patients with aortitis from receiving cardiac surgery.
- Advancements in medical and surgical treatments of Takayasu arteritis-induced renal arteritis: a systematic review.
- CYR61/TGF-β axis promotes adventitial fibrosis of Takayasu's arteritis in the IL-17 mediated inflammatory microenvironment.
- The potential role of leflunomide in inhibiting vascular fibrosis by down-regulating type-II macrophages in Takayasu's arteritis.
- The value of interleukin-6 in predicting disease relapse for Takayasu arteritis during 2-year follow-up.
- Efficacy and safety of leflunomide treatment in Takayasu arteritis: Case series from the East China cohort.
- Takayasu arteritis risk locus in IL6 represses the anti-inflammatory gene GPNMB through chromatin looping and recruiting MEF2-HDAC complex.
- Value of contrast-enhanced ultrasonography of the carotid artery for evaluating disease activity in Takayasu arteritis.
- YKL-40 as a new biomarker of disease activity in Takayasu arteritis.
- Serum leptin, a potential predictor of long-term angiographic progression in Takayasu's arteritis.
- Radiology and biomarkers in assessing disease activity in Takayasu arteritis.
- Autophagy promotes aortic adventitial fibrosis via the IL-6/Jak1 signaling pathway in Takayasu's arteritis.
- Pro-fibrotic effect of IL-6 via aortic adventitial fibroblasts indicates IL-6 as a treatment target in Takayasu arteritis.
- Analysis of predictive factors for treatment resistance and disease relapse in Takayasu's arteritis.
- 18F-FDG-PET/CT: an accurate method to assess the activity of Takayasu's arteritis.
- Treatment of Takayasu arteritis with the IL-6R antibody tocilizumab vs. cyclophosphamide.
- Cyclophosphamide could be a better choice than methotrexate as induction treatment for patients with more severe Takayasu's arteritis.
- The critical role of IL-6 in the pathogenesis of Takayasu arteritis.
- Value of whole-body contrast-enhanced magnetic resonance angiography with vessel wall imaging in quantitative assessment of disease activity and follow-up examination in Takayasu's arteritis.
- Celiac Artery Stenting in the Treatment of Intestinal Ischemia Due to the Sacrifice of the Dominant Inferior Mesenteric Artery During Endovascular Aortic Repair.
- [A comparative study of diagnostic efficacy of different diagnostic/ classification criteria in Takayasu arteritis].
All its trials on ClinicalTrials.gov, any status8
- A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis
- A Pilot Study in Severe Patients With Takayasu Arteritis.
- Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis
- Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients
- Drug-coated Balloon for Takayasu Arteritis Associated Renal Artery Stenosis
- The Registry Study of Takayasu Arteritis in East China
- A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)
- Takayasu Arteritis Clinical Trial in China
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 3 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
34 hospitals in Shanghai for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis
No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- Transcriptomic profiles of single-cell autophagy-related genes (ATGs) in lung diseases.
- Unveiling the role of copper metabolism and STEAP2 in idiopathic pulmonary fibrosis molecular landscape.
- Medium-long term prognosis prediction for idiopathic pulmonary fibrosis patients based on quantitative analysis of fibrotic lung volume.
All its trials on ClinicalTrials.gov, any status6
- A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary Fibrosis
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Other diseases
Lymphangioleiomyomatosis
肺淋巴管平滑肌瘤病Led 1 of the 45 English-language PubMed papers on lymphangioleiomyomatosis with an author in mainland China, 2021–2025: 2.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Shanghai for lymphangioleiomyomatosis28 hospitals in China for lymphangioleiomyomatosis
No open trial on lymphangioleiomyomatosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 3 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
17 hospitals in Shanghai for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis
No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- Machine learning-based proteomics profiling of ALS identifies downregulation of RPS29 that maintains protein homeostasis and STMN2 level.
- Potential Correlation between Tea Intake and the Risk of Amyotrophic Lateral Sclerosis: A Mendelian Randomization Study.
- Comparison of neurofilament light and heavy chain in spinal muscular atrophy and amyotrophic lateral sclerosis: A pilot study.
Other diseases
Duchenne muscular dystrophy
杜氏肌营养不良Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
12 hospitals in Shanghai for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy
No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Other diseases
Behçet disease
白塞病Led 2 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
15 hospitals in Shanghai for Behçet disease149 hospitals in China for Behçet disease
No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
All its trials on ClinicalTrials.gov, any status1
Other diseases
IgA nephropathy
IgA 肾病Led 4 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
26 hospitals in Shanghai for IgA nephropathy346 hospitals in China for IgA nephropathy
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
- Phase
- Early phase 1
- Started
- 2025-07
- Registry
- NCT07203404
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led4
- Does Bi-exponential Fitting Perform better than Mono-exponential Fitting in IVIM-DWI? An Assessment of Renal Pathological Injury of IgA Nephropathy.
- Serum soluble interleukin-2 receptor alpha may predict tubulointerstitial inflammatory cell infiltration and short-term disease progression in immunoglobin A nephropathy.
- Urinary N-Acetyl-Beta-D-Glucosaminidase levels predict immunoglobulin a nephropathy remission status.
- Urinary Soluble CD163 Levels Predict IgA Nephropathy Remission Status.
Earlier papers (2016–2020)4
- Immunosuppressive agents in the treatment of IgA nephropathy: A meta-analysis of clinical randomized controlled literature.
- Corticosteroid therapy in IgA nephropathy with minimal proteinuria and high renal pathological score: A single‑center cohort study.
- Elderly patients with glomerular diseases and IgA nephropathy.
- miR-382 Contributes to Renal Tubulointerstitial Fibrosis by Downregulating HSPD1.
All its trials on ClinicalTrials.gov, any status4
- A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
- A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
- A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy Subjects
- Comparison of HRS-5965 Capsules and Tablets in Healthy Subjects
Other diseases
Osteogenesis imperfecta
成骨不全症Led 1 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 1.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Shanghai for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta
No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
17 hospitals in Shanghai for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis
No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
Inherited epidermolysis bullosa
遗传性大疱性表皮松解症Led 1 of the 56 English-language PubMed papers on inherited epidermolysis bullosa with an author in mainland China, 2021–2025: 1.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
7 hospitals in Shanghai for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa
No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Other diseases
Familial adenomatous polyposis
家族性腺瘤性息肉病Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
9 hospitals in Shanghai for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis
No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)3
- Familial juvenile polyposis syndrome with a de novo germline missense variant in BMPR1A gene: a case report.
- Gene mutation-based and specific therapies in precision medicine.
- Intestinal perforation during chemotherapeutic treatment of intra-abdominal desmoid tumor in patients with Gardner's syndrome: report of two cases.
All its trials on ClinicalTrials.gov, any status1
Other linked evidence
Getting in touch
Name card to show staff or a driver
复旦大学附属中山医院
Zhongshan Hospital, Fudan University
上海
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR Wikidata
Zhongshan Hospital; Zhongshan Hospital of Fudan University; Liver Cancer Institute and Zhongshan Hospital; Zhongshan Hospital Fudan University; Zhongshan Hospital (Xiamen); Zhongshan Hospital Affiliated to Fudan University; Zhongshan Hospital and Shanghai Medical School; Liver Cancer Institute & Zhongshan Hospital